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ABSTRACT 
 
Background:  The prostate specific antigen (PSA) test has been available for 
physicians and free of charge to residents in Saskatchewan since 1990.  The PSA test 
witnessed great growth in use indicative of screening but it was unknown who was being 
tested, how often, which physicians were ordering PSA tests, or what the variation in 
utilization was in the population.  Whether widespread use of the PSA test resulted in a 
stage shift among newly diagnosed prostate cancers or changed the clinical management 
of the disease was also unknown.  The purpose of this research was to describe in detail 
how the PSA test is being used in the Saskatchewan population and investigate the 
impact of testing on the diagnosis and clinical management of prostate cancer during the 
PSA era.  
Methods:  Individual records were retrieved from the two labs in Saskatchewan 
capable of analyzing PSA serum samples.   The PSA data represented almost all PSA 
tests in the population for the five-year period 1997-2001.  The PSA data included date of 
the PSA test, a unique identifier of the men tested, test results including total PSA and the 
free-PSA amount (for November 1999 to December 2001), and an ID of the physician 
who ordered the test.  This data was linked to the population-based Saskatchewan Cancer 
Registry to determine who had a previous or subsequent prostate cancer diagnosis and to 
secure tumour characteristics and clinical management data.  This combined data was 
then linked to Saskatchewan Health data files to obtain information about biopsy 
procedures and to determine the geographic residence of men at the time of their PSA 
tests.  De-identified data was returned for descriptive analysis.  
Results:  Over 60% of men aged 50 and over had at least one PSA test during 
1997 to 2001.  Even among men 40-49, 27% had at least one PSA test and there were 
over 5,300 tests done in men under 40 years of age.   Sixteen percent of men 40-49 who 
had PSA tests had more than one and this percentage increased with age to 59.4% for 
men in their 70’s.  Over 80% of all PSA tests were ordered by general practitioners and 
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there were significant geographic variations in testing patterns.  Knowledge of the free-
PSA-ratio, which began in 1999, reduced biopsy rates 4.7% and increased cancer 
detection 8.7% for men with total PSA test results in the 4.0-10.0ng/ml range, however 
these rates were also very age specific.  The age-adjusted incidence rate of organ 
confined disease increased from 38.5 per 100,000 to 108.8 per 100,000 from 1985 to 
2001.  Almost 80% of prostate cancers were detected by needle biopsy in 2001 compared 
to only 34% in 1985, while 20% of cases in 2001 were treated with radical surgery 
compared to only 2% for 1985.  Mortality rates have remained stable up to 2001. 
Conclusion:  PSA testing is very common in Saskatchewan consistent with 
extensive screening activity.  Conflicting guidelines and the universal availability of the 
test has resulted in significant inappropriate testing and considerable variation of use.  
Most prostate cancers are now found by needle biopsy and are organ confined at the time 
of diagnosis.  No benefit in prostate cancer mortality has yet been realized in 
Saskatchewan from extensive PSA testing. 
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GLOSSARY OF TERMS 
 
Invasive:  Cancer that has spread beyond the tissue of origin and is growing into 
surrounding healthy tissues. 
Incidence:  The number of new cases of a disease diagnosed each year 
Mortality:  For the purposes of this research, primary cause of death reported on death 
certificates. 
Prevalence: the number of events (for this research, men in the population with known 
prostate cancer) at a point in time.  
Metastasis: The spread of cancer from one part of the body to another.  The metastatic 
tumor contains cells that are like those in the original tumor. 
Local disease (cancer): The spread of cancer from the site or origin to nearby tissues.  
Stage:  The extent of a cancer in the body.  Stage at time of diagnosis is usually based on 
the size of the tumor at diagnosis, whether the cancer has spread from the original site to 
or to other parts of the body. 
Grade:  The grade of a tumor is a measure of the abnormality of the cancer cells as 
viewed under a microscope and reflects how quickly the tumor is likely to grow and 
spread. Grading systems are different for each type of cancer. 
Gleason Score: A system of grading prostate cancer tissue based on how it looks under a 
microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor 
will spread. A low Gleason score means the cancer tissue is similar to normal prostate 
tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue 
is very different from normal and the tumor is more likely to spread. 
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1.0 INTRODUCTION AND BACKGROUND 
Prostate specific antigen (PSA) is a glycoprotein produced by prostatic epithelial 
cells. Elevated levels of PSA in blood serum are associated with prostate enlargement and 
indicate increased risk of prostate cancer.  The PSA test was developed to measure the 
level of PSA in serum and initially was used as a follow-up test for men with prostate 
cancer.  However, because of the association of elevated PSA with increased risk of 
cancer, the test over time is now commonly used as a screening tool for the early 
detection of prostate cancer.  Two large screening trials were initiated, one in the United 
States and the other in Europe, to investigate whether screening for prostate cancer with 
PSA provides any mortality benefit from prostate cancer but thus far, neither have 
provided definitive results.1, 2 
In Saskatchewan, the PSA test became available for physicians to use for their 
patients in 1990 and the test was covered by the provincial health plan, making it free of 
charge to the patient.  This created a rather unique situation, where all residents had 
access to the PSA test at no cost.  The use of the PSA test grew dramatically and during 
the time period after its introduction, prostate cancer rates in Saskatchewan rose 
substantially.3 
This thesis work will take advantage of existing population-based databases to 
investigate PSA test use and outcomes associated with this testing activity in 
Saskatchewan, which has never been reported.  Three projects are contained in this thesis 
and each project is provided as a separate chapter in the style of a manuscript. The 
projects, collectively, explore how the PSA test has been used in Saskatchewan; what 
physician groups order the PSA test and who is being tested; what variations are there in 
the population of men being tested in terms of geography, frequency of testing, age 
distribution; what are the test results and how do they distribute in the population of men 
tested?  As well, this thesis work will provide a description of the outcomes of PSA 
testing in the Saskatchewan population, in terms of changes in cancer detection, tumour 
characteristics of newly diagnosed prostate cancers, and clinical management.   
2 
Many of these questions remain unanswered in jurisdictions where PSA testing is 
commonly used.  This work will provide important information about widespread PSA 
testing in a population where the test is freely available but where screening is not 
actually fully endorsed.  It is unknown whether our testing patterns reflect any of the 
screening guidelines that exist from organizations that have put forward 
recommendations on the early detection of prostate cancer.   
This Introduction and Background section is followed by a brief description of the 
research and then by a literature review on the subject of PSA testing and the key issues 
associated with prostate cancer screening.  After the literature review are three chapters, 
each one a specific project investigating the elements of the issues mentioned above.  
Finally a Discussion and Conclusion section will summarize the findings of this research 
and provide recommendations about potential next steps in the Saskatchewan context.  
1.1 Prostate Cancer: Burden of Disease in Saskatchewan 
The prostate is a chestnut shaped gland found at the beginning of the urethra in 
males.  One of its main functions is the production and secretion of fluid that makes up 
about a third of the volume of semen that a male ejaculates.  The prostate is also a 
common site of cancer in men.  The risk of disease increases with increasing age.  The 
following section describes the burden of disease of prostate cancer in Saskatchewan in 
terms of incidence, mortality, years of life lost, and trends over time.  
Prostate cancer is the most common invasive cancer diagnosed in Saskatchewan 
males.  Among 2,429 new cases of invasive cancer diagnosed in men in 2002, 771 cases, 
or almost exactly one in three were prostate cancer.4  Overall, prostate cancer represents 
about 17% of all new invasive cases per year in the Saskatchewan population including 
females.  The burden of this disease has increased over time, in part, because of its strong 
association with increasing age, and the ageing of the Saskatchewan population.4, 5 
Figure 1.1 shows the age-specific incidence rates for prostate cancer in 
Saskatchewan in 2002.  After age 50, incidence increases dramatically.  There are now 
also many more men in Saskatchewan over age 50 than ever before.  In 1970, there were 
112,562 men age 50 or older and by 2002, this number was 140,692, an increase of 25 
percent.5  Given the aging population of Saskatchewan, the burden of prostate cancer is 
expected to increase in the foreseeable future. 
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The distribution of the most common cancers in Saskatchewan men has changed 
over time (Figure 1.2).5  In the 1950-1954, prostate cancer was the most common 
invasive cancer representing 15% of cases, but cancers of the lip and stomach were very 
close in terms of absolute numbers.  In 1997-2001, prostate cancer was twice as common 
as lung cancer, the second leading site, and accounted for 30% of all invasive cases 
diagnosed in males.   
Incidence and mortality trends for prostate cancer show different patterns in 
Saskatchewan and between Saskatchewan and Canada overall.  The age-adjusted 
incidence rate in Saskatchewan showed marked increase beginning in 1990, coinciding 
with the introduction of the PSA test (Figure 1.3).4, 6  A peak in incidence was reached in 
1993 followed by a drop to previous levels. A similar pattern occurred in Canada, 
however the peak was not as great as was experienced in Saskatchewan.  Following a 
three-year period of stability, the incidence in Saskatchewan again began to increase 
quickly and by 2001 had again reached peak levels previously seen in 1993.  In Canada, 
the “wave” began at the same time but again was less steep and did not reach the same 
peak as witnessed in Saskatchewan.  Similar patterns had been observed in other 
jurisdictions, with the magnitude of change likely related to the amount of PSA testing in 
those areas.7   
The sharp increase in incidence rates (50% from 1990 to 1994) followed by the 
return to previous trends is very indicative of a screening effect in the population.8  In the 
presence of (new) screening activities, the number of new cases diagnosed of the target 
disease usually increases because the activity identifies more of the prevalent cases (the 
number of cases in existence in the population at a given point in time) in the population, 
which would not have been identified in the absence of screening.  After some time, the 
incidence returns to previous levels and trends, once the prevalent cases have been 
identified and most of the target population has been tested.8 
Although incidence has changed significantly over time, the trend in prostate 
cancer mortality has been almost constant (Figure 1.3).  There had been little difference 
in mortality rates between Saskatchewan and Canada from 1983 to 1994.  Since 1994 
though, mortality rates in Canada have decreased whereas they remained stable in  
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Saskatchewan.  Decreases in prostate cancer mortality might result from the screening 
activity of the 1990’s if cancer was diagnosed at earlier stages with better prognosis. But 
mortality improvements would not be realized for years given the overall five-year 
relative survival is about 82%.3, 9  As well, the lead time (time gained by detecting cancer 
earlier than usual because of screening) associated with PSA screening has been 
estimated to be between 5 and 9 years, therefore if mortality decreases at all, this would 
likely not be realized until sometime in the mid 2000’s.10  Whether any benefit of prostate 
cancer screening is possible is currently a highly contested issue.11, 12  
Potential-years-of-life-lost (PYLL) is another measure of disease burden.  PYLL 
measures the loss in a society due to early death.  The calculation of PYLL was based on 
provincial life tables published by Statistics Canada.13  The annually published life tables 
indicate for each sex in Saskatchewan, the life expectancy in years for each single year of 
age (e.g. 50, 51, 52).  People who died of cancer were matched to the life tables based on 
age (single year) at time of death, sex, and year.  The total and average PYLL due to 
various cancer sites for men in Saskatchewan are shown in Figure 1.4.  The total PYLL 
from prostate cancer for the period 1997-2001 was second only to lung cancer for men.  
For this period, there was 9,585 PYLL due to prostate cancer.  On average however, 
PYLL due to prostate cancer is significantly less than many other cancer sites.  The total 
PYLL is high because there are many deaths attributed to prostate cancer, but the average 
PYLL per person is lower because deaths are generally in much older men, who typically 
would not expect to live many more years, compared to deaths in men that are caused by 
other cancers. 
1.2 Prostate Specific Antigen Test: Background in Saskatchewan 
Prostate cancer witnessed continued growth in incidence over the past fifty years, 
but none larger than in the 1990s, a time coinciding with the introduction of the serum 
prostate specific antigen (PSA) test in 1990.  The PSA test was initially used in other 
jurisdictions in the 1980s as a follow-up test to investigate disease recurrence and 
progression for men with prostate cancer.  This important use remains today but the 
utility of the test expanded in the late 1980s and 1990s to include early diagnosis and 
screening, albeit under much controversy.  
8 
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The PSA test became available to physicians in Saskatchewan in 1990.  The test 
itself was covered by provincial health insurance meaning all residents could receive the 
test free of charge.  This is still the case as of 2008.  Initially, the Pasqua Hospital in 
Regina was the only facility in the province able to analyze blood samples for PSA.  The 
Royal University Hospital (RUH) in Saskatoon became equipped to analyze these blood 
samples a number of years later; however initially most samples were follow-up tests 
coming from the Saskatoon Cancer Centre for men with known prostate cancer. 
In the fall of 1999 the Pasqua Hospital began providing physicians the amount of 
PSA not bound to other serum proteins, along with the total PSA amount as usual.  This 
unbound PSA is reported to physicians as a ratio of the free-to-total PSA and is known as 
the free-PSA (fPSA) or free-PSA ratio, which literature has indicated provides an 
improvement in the sensitivity and specificity when screening for prostate cancer over 
total PSA alone.14  Appendix 1 shows the information provided to physicians with each 
fPSA test result.   
The Pasqua Hospital lab provided this additional information for every serum 
sample where the total PSA was in the diagnostic grey zone of 4.0ng/ml to 10.0ng/ml.  
This is a grey zone because anything over 4.0ng/ml is considered high but many men will 
actually not have cancer, while over 10.0ng/ml, cancer is much more common.15  At the 
Royal University Hospital in Saskatoon, provision of the fPSA information did not occur.  
by 1999 however, more serum samples were being sent to the RUH from the community 
physicians (early detection) and not strictly from Saskatoon Cancer Centre (follow-up of 
cancer patients).  Still, a majority of community-based testing was analyzed at the Pasqua 
Hospital. 
At the Pasqua Hospital the number of PSA samples analyzed grew exponentially 
from 1990 to 1994.  In 1990, approximately 600 tests were analyzed and by 1994 this 
number grew to over 48,000.3  Blood samples were coming from physicians from all 
areas of the province.  The sheer volume and the distribution of the referring physicians 
suggested strongly that the test was being used for screening purposes.  In 1995, the 
Health Services Utilization and Research Commission introduced provincial guidelines 
for the use of the PSA test.  The guidelines, while voluntary for physicians, recommended 
10 
against using the PSA test for screening asymptomatic men of any age because the test 
had a high false positive rate and there was no evidence from randomized trials that early 
detection of prostate cancer improved mortality.16   
The number of PSA tests dropped for the first time, but soon after the volume 
began to increase again to over 80,000 tests (both hospitals) by 2001.  Over the same time 
frame, a corresponding increase occurred in the number of prostate cancers diagnosed.  In 
1989 there were just over 500 cases in Saskatchewan but by 2001, that number had 
grown to 840 cases, an increase of over 60 percent.   
There are conflicting guidelines available about screening for prostate cancer.  In 
Canada, routine screening for prostate cancer is still not recommended.17  However, the 
American Cancer Society promotes prostate cancer screening using the PSA test.18  In 
Saskatchewan, the decision to screen ultimately rests with men in consult with their 
physicians. 
1.3 Prostate Cancer: Etiology 
The greatest risk factor for prostate cancer is increasing age as shown in  
Figure 1.1.  Autopsy studies have shown that cancer of the prostate may be present in as 
many as 70% of men over 80 years of age.19  However, many of these cancers are likely 
to be clinically latent, in other words disease with histopathologic features of malignancy 
but with very low potential for growth and metastasis (ability for a cancer to spread to 
other parts of the body which usually results in death); in other words, cancers with low 
risk of causing death prematurely.  These cancers are fairly common in older men who 
often die of other causes without ever having a diagnosis of prostate cancer.20 
Ecologic studies have implicated the “western lifestyle” with increased prostate 
cancer risk.  Studies of migrants moving from areas of lower prostate cancer incidence to 
areas of higher incidence are often found to assume a risk closer to that present in the new 
area.21, 22  This could be brought about by changes in environmental exposures and\or 
changes in lifestyle including diet.  Diet has been investigated as an etiologic factor in 
numerous studies with mixed results.   
Some dietary components are consistently found associated with prostate cancer.  
High fat intake seems related to prostate cancer but most studies do not account for total 
energy intake.  High fat intake may be related or may represent a low intake of protective 
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nutrients.  As well, fat comes from different sources such as dairy products or meat.  Fat 
from dairy products might be related to increased risk but high calcium intake has also 
been shown to increase risk as an independent factor, making specific inferences about 
the role nutrients play in prostate cancer difficult.22, 23  
Red meat has been shown in some studies to increase risk but the effects of fat or 
other constituents of animal-fat in foods may be also related to prostate cancer.  It is also 
possible that the intake of meat may not be the cause, but rather the cooking method used 
to prepare the meat.  Charcoal grilling or frying at high temperatures has been shown to 
produce heterocyclic amines, which are known carcinogens and have yet to be studied in 
relation to their impact on prostate cancer.23  
While some dietary components may increase risk of prostate cancer, others may 
also reduce risk.  Some studies suggest that tomato-based foods may decrease risk 
provided that the tomato is cooked or processed into sauce, soup or ketchup.24  Lycopene 
is a strong antioxidant in tomatoes that is more bioavailable when tomatoes are cooked 
and eaten rather than when eaten raw.22   
Nutrients such as selenium and vitamin E have shown some promise in reducing 
prostate cancer risk.  Selenium is known to inhibit tumorigenesis (production of new 
growth) in prostate cancer by several possible mechanisms including antioxidant effects, 
induction of apoptosis (programmed cell death), immune responses, and effects on 
testosterone production.23  Vitamin E or alpha-tocopherol was shown in a Finnish 
prevention trial to reduce incidence and mortality from prostate cancer by 32 and 41 
percent, respectively.25  The results are encouraging but should be viewed with caution 
however, since the cohort under study was older male smokers, therefore not easily 
generalizable to whole populations.  
There is good evidence that family history is associated with prostate cancer 
risk.22, 23  Men with first-degree relatives with prostate cancer are at greater risk of 
disease.  The risk seems to increase if more than one first-degree relative is affected and 
if the cancer occurs in ages under 60 years.  This increased risk is reflected in some 
screening guidelines, where men are encouraged to begin PSA testing at younger ages if 
they have a first-degree relative diagnosed at younger age or if they have multiple first-
degree relatives diagnosed at younger ages.18 
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1.4 Prostate Cancer: Methods of Clinical Diagnosis 
Prostate cancer is diagnosed in a variety of ways.  In older men, the cancer is 
sometimes clinically identified using transrectal ultrasound without histologic 
confirmation.  Most often however, biopsies of the prostate would be performed to 
confirm with tissue samples whether cancer was present. 
Prostate cancers are also commonly detected at autopsy.  The prevalence of latent 
cancer is very common in older men and is often detected at autopsy even though the 
cause of death was unrelated to the cancer.  Even though the incidence of prostate cancer 
varies considerably worldwide, there is indication that the prevalence of latent prostate 
cancer is more similar.  This suggests that the initial steps in carcinogenesis may be the 
same in different populations but differences may exist in factors that promote 
progression.26 
Prostate cancer incidence increased steadily during the 1970s and 1980s 
throughout North America prior to the PSA era.  The increase has partially been 
attributed to increasing rates of transurethral resections (TURP) of the prostate to 
alleviate symptoms of benign prostatic hypertrophy.  Given the high prevalence of latent 
prostate cancer, increasing numbers of TRUS procedures subsequently lead to more 
incidental diagnoses of prostate cancer.27 
1.5 Prostate Cancer: Treatment Options 
Men with early stage prostate cancer have more treatment options than most 
cancer patients.  There are four primary treatments that include radical prostatectomy 
surgery, radiation therapy, hormonal therapy, or watchful waiting.  Watchful waiting 
(close monitoring of disease without radical treatment) is a viable alternative because of 
the unique epidemiology of prostate cancer.  Prostate cancer occurs in older men and in 
many cases these cancers are slow growing with low potential for metastasis.28  Watchful 
waiting may be appropriate for men who will eventually die of other causes.  Choosing 
initial treatment however is difficult given each therapy has their own host of side effects 
and risks associated with them.  Also making the choice difficult is the current lack of 
evidence that any one of the treatments is better than the others.29 
 Choosing treatment is complex and requires much patient education of the risks 
and potential benefits.  Surgery has the potential to remove the entire tumour in localized 
13 
cases but the side effects can include sexual and urinary complications.  Men who choose 
radiation therapy may experience those problems to a lesser degree but are more prone to 
bowel dysfunction.30, 31    
Some studies have investigated treatment outcomes for men with localized 
disease.  Local disease has been the focus of study since these represent the vast majority 
of cases since the introduction of the PSA test in the late 1980s.  Harlan and colleagues 
investigated the factors that predict treatment choice in men from the National Cancer 
Institute’s Prostate Cancer Outcomes Study and found that most men older than 75 years 
received conservative treatment.32  Factors associated with conservative treatment after 
adjusting for age, stage, grade, and PSA level included history of heart attack, unmarried, 
geographic region, poor pre treatment bladder control, and impotence.     
The treatment decision is more complex in younger men with typically at least 10 
years of life expectancy.  Johansson et al showed that for men who initially had untreated 
prostate cancer, there was little change in disease progression for the first 10 to 15 years 
after diagnosis, but after 15 years, there was a decrease in progression-free survival, 
survival without metastases, and prostate cancer-specific survival.33  The prostate cancer 
mortality rate increased by a factor of three after 15 years compared to the first 15 years 
of follow-up.  Radical treatment was suggested as initial treatment for men with a 15 year 
life expectancy.  
A clinical trial investigated the difference in outcomes for men under 75 who had 
local disease and at least 10 years of life expectancy.34  Patients were randomized to 
surgery or watchful waiting.  After ten years of follow-up, the surgery group had 
statistically better prostate cancer-specific survival (30 deaths from prostate cancer 
compared to 50, respectively) and better overall survival (83 total deaths compared to 103 
total deaths in watchful waiting group).  As well, the surgery group had lower rates of 
metastasis development and development of local progression.  So while prostate cancer 
mortality was reduced, this had no impact on overall survival after eight years of follow-
up.  
Given these treatment choices and the seeming equality of outcomes, the focus for 
many men with prostate cancer is maintaining quality of life.  Each treatment has its own 
array of potential side effects and men need to be educated about the risks and benefits of 
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each.  Conservative management for men with local disease and Gleason scores (grading 
scheme for prostate cancer that classifies tumours by their level of cellular differentiation; 
the scores are the sum of two most dominant patterns each rated on a score of 1 to 5) of 
2-4 was found to produce better quality-adjusted life years over radically treated men in a 
simulation study.  For cases with Gleason scores of 5-6, results were similar, and for 
Gleason scores of 7 to 10, radically treated patients were projected to have better quality-
adjusted life years than conservatively treated patients.35 
Educating men about their options and the risks and benefits of different 
treatments is required for informed decision making.  Sculpher et al showed using 
discrete choice experiments, that men with at least five years life expectancy, local 
disease, and who would be eligible for different treatments, were willing to trade off 
some life expectancy to reduce the burden of some side effects, especially limitations in 
physical energy.36  Enabling informed decision making however, requires comprehensive 
patient education.  A recent cross-sectional review of publicly available materials about 
prostate cancer treatments, risks, and benefits for early stage disease indicates that current 
education materials do not contain comprehensive information about the risks and 
benefits of each treatment.37  This review however was limited to materials available 
from the internet, print, and multimedia sources.   
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2.0 RESEARCH PROJECTS 
There has been no detailed analysis of the impact of PSA testing on prostate cancer 
in the Saskatchewan population even though the PSA test has been used for almost 18 
years to this point.  As well, no study has been done on the utilization of the PSA test in 
Saskatchewan or what impact was witnessed after 1999 when the fPSA ratio was 
incorporated.  The three research projects described below provide unique insight about 
PSA use and its impact on prostate cancer diagnosis, relevant not only to Saskatchewan, 
but to other populations where the test is available free of charge.  
The first project takes advantage of individual level recorded data from the labs in 
Saskatchewan to investigate in detail the testing patterns and test results among men, and 
about characteristics of physicians who ordered the tests.  Very little is reported in the 
literature about PSA testing at the population level due to unavailability of data.  The 
study provides information about the men tested according to age at time of test, 
frequency of repeat testing in men over time, geographic variation and as well the 
distribution of test results for the five-year period 1997-2001.  The research also indicates 
the testing patterns among ordering physicians.  The results are based on individual 
recorded data from population repositories, not survey or clinic\hospital based 
information.  This research provides unique information about the actual use of the PSA 
test at the population level where the test is freely available to all men. 
The second project is an extension of the first project and also takes advantage of 
individual level recorded data.  This study also capitalizes on the natural experiment that 
took place with the Pasqua Hospital lab, in Regina, Saskatchewan, Canada, that began 
reporting the fPSA ratio on all serum samples that were in the 4.0ng/ml to 10.0ng/ml 
range in 1999.  The data provides an opportunity to see the immediate impact of 
providing the additional fPSA ratio information to physicians.  Of interest in this study 
was the comparison of pre and post age-specific biopsy and cancer detection rates given 
the additional fPSA information.  Other than this provision, all else remained the same in 
Saskatchewan, so changes in practice or outcomes would certainly be attributed to 
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providing the fPSA ratio.  Again, unlike other studies which investigated the fPSA ratio 
as a supplemental marker for prostate cancer, this research is unique by its population-
based focus and universal availability. 
The third and final project provides a detailed description of the changes in case 
mix and treatment patterns that occurred during the PSA era (1990 forward) compared to 
the time prior to PSA testing.  This study indicates the impact PSA testing has had on the 
key prognostic characteristics such as stage and grade of disease at diagnosis and as well, 
how treatment patterns have changed in Saskatchewan before and during the PSA era.  
Stage migration following PSA testing in the population has been well documented in 
other jurisdictions where PSA testing is common; this work reveals the impact of PSA 
testing in Saskatchewan.  As well, the research shows how the management of the disease 
has changed in the PSA era.  Project 3 reveals how incidence, tumour characteristics and 
clinical management change in a population exposed to extensive PSA testing.  
Much has been written about screening for prostate cancer over the last 10 years.  
At present, a search of the US National Library of Medicine’s PubMed website for 
articles related to “prostate cancer” and “screening”, will retrieve no less than 2700 
titles.38  Two major screening trials are underway investigating the PSA test for screening 
but so far, no mortality benefit from these trials have been published.  In the meantime, 
researchers are looking at surrogate measures of both benefit and harm from PSA 
screening.  A vast majority of this work however is not population-based, and the 
circumstances under which men are tested vary considerably.  This research provides 
unique information about PSA testing in a population where the test is universally 
available free of charge to the patient.  
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3.0 GENERAL LITERATURE REVIEW 
For the purposes of this research, PubMed was searched using the search terms 
“prostate specific antigen” and “screening”.39  Limits used included being published in 
last five years, English language, humans, male, and cancer.  This generated 861 article 
titles for potential review.  After reviewing the titles and abstracts, 92 articles were 
included for review.  Most of the articles not selected were more focused on very specific 
biologic or treatment mechanisms and less focused on actually screening or early 
detection subject matter.  Additionally, relevant articles were reviewed from the 
references in the selected articles.  
The articles retained for further review fell into five categories as they relate to this 
research.  The first group of studies reviewed focused on general issues around screening 
for prostate cancer with PSA based primarily on observational research since on-going 
screening trials are incomplete.  The second group of studies included research that 
reported on PSA use, or estimates of use, in populations.  The third category included 
studies that investigated strategies to improve the performance of the PSA test, for 
example using the fPSA ratio.  The fourth grouping included studies researching 
outcomes from prostate cancer screening with PSA.  Outcomes were not limited to only 
mortality reductions, but included other measures such as stage migration and changes in 
incidence of metastasis at diagnosis.  The last category focused on informed decision 
making for patients.  Many of the current guidelines that exist suggest proceeding with 
PSA testing only when the patient is informed of the potential benefits and as well the 
potential harms.  
3.1 General Screening Issues 
The amount written about prostate cancer screening is now extensive and the 
controversy around screening has not subsided at all over the last 10 years.  The debate 
about whether to do screening using PSA testing stems from the lack of evidence of 
mortality benefit from two large ongoing screening trials.  The Prostate, Lung, 
Colorectal, and Ovary Cancer Screening trial in the US (PLCO) and the European 
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Randomized Study of Screening for Prostate Cancer (ERSPC), have both been recruiting 
men for PSA screening with over 10 years of follow-up.1, 2  Both trials are expected to 
publish results sometime in 2009.   
The controversy about PSA screening for prostate cancer will remain until some 
definitive answer about screening is provided from these trials.  The trials however are 
not exactly the same and they might be answering slightly different questions when 
completed.  The PLCO in the US does PSA screening on enrolled men followed by usual 
care when abnormal tests are generated.  There is concern that given widespread use of 
PSA testing in the US over recent years, the control group is likely to be contaminated by 
men who are in fact screened.40  If so, the magnitude of effect will need to be that much 
greater to find an effect of screening on mortality.40  The ERSPC however is less likely to 
suffer from contamination in the control group because PSA use is not as common in the 
European countries involved in the trial.  The ERSPC does have a protocol in place for 
the follow-up of abnormal tests and indications for biopsy, and so might not be as 
generalizable to the overall population.40 
Barry has provided a good description of the screening debate and how PSA has 
changed the landscape of prostate cancer.40  The lifetime risk of prostate cancer has 
changed from 10% to 18% in American men because of increased detection of disease 
from PSA testing.  Although there is greater cancer detection, we still don’t know if 
screening and aggressive treatment will reduce mortality enough to warrant the increase 
in morbidity that also results from side effects of treatment (sexual dysfunction and 
incontinence).  It has been noted that prostate cancer mortality has recently been 
dropping, but this varies considerably in US regions and does not necessarily correlate to 
PSA use in these regions.  As well, the UK has seen a drop in mortality as well, where 
PSA testing is much less common.40 
It is interesting to note the paradigm shift in clinical care that seems to have 
occurred with PSA testing and screening.  Previously, with mammography, screening 
was only endorsed and pursued after completion of trials that showed mortality benefit 
from mammography screening.  The notion was as Barry concluded, “don’t screen until 
trials prove its effectiveness”.  In the case of PSA screening and in particular North 
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America, the notion seems to be “screen until trials prove it doesn’t work, then stop 
(maybe)”.40 
The debate about screening is very much alive and well, especially in North 
America.  In Canada a very recent debate on the subject was provided by Fradet versus 
Labrecque and Légaré.41,42  Fradet claimed in his argument that radical prostatectomy and 
PSA screening reduces mortality from prostate cancer.  Labrecque and Légaré argued that 
there is minimal effect of radical prostatectomy and that any mortality reductions in the 
population can’t be assigned to PSA testing.  They also argued that at this point in time, 
physicians do not know which prostate cancers are the aggressive ones requiring 
treatment and which ones will not result in death from prostate cancer i.e. not requiring 
aggressive treatment.  The general practitioner camp also seemed more supportive of 
informed decision making as long as correct and balanced information was provided to 
patients.42 
The arguments were very telling, with urology on one side 43 and general 
practitioners on the other side.44  With so much literature on prostate cancer screening 
available, either side can find articles to support their claims.  What is most noteworthy 
are the different interpretations both sides provide on the same published research!   
The medical debate has certainly not been confined to Canada.  A similar recent 
debate occurred in the US as well, between urologists Catalona, Loeb and Han versus 
general practitioners represented by Hoffman from Veteran Affairs.45, 46  Catalona et al 
provided a very aggressive stance on PSA screening, not only arguing that the evidence is 
“convincing” for screening, but that the age of testing should be lowered to 40 years from 
the current US practice of 50 years.  As well they recommend that screening be provided 
to men over 70 years of age providing they are healthy and that for all cases, the cutoff 
for abnormal be lowered from 4.0ng/ml to 2.5ng/ml of total PSA.  As was witnessed in 
the Canadian debate, Hoffman claimed the evidence was “unconvincing” and argued 
against lowering both the age of testing and the threshold for defining “abnormal”.  
Again, both sides reviewing similar research material come to very different conclusions.  
Where are these different viewpoints coming from, and what spurs them on?  It is 
hard to argue that some professional groups such as urology don’t have a vested interest 
in treatment of prostate cancer.  But we can’t paint all urologists with the same brush, 
20 
certainly some do not support widespread screening for prostate cancer.  So what is the 
issue, why are there such different opinions?  Part of the reason is certainly lack of 
screening trial evidence, leaving physicians to wade through the evidence themselves and 
coupled with their own personal beliefs, render a yay or nay on the screening issue.  It has 
been pointed out very recently that of the 19 medical organizations worldwide with 
recommendations on the issue, only three endorse PSA screening.47  Two of these three 
have a conflict of interest; the American Urologic Association and the French Urologic 
Association, who both recommend annual PSA testing for men over age 50.  The other 
group to endorse is the American Cancer Society but they do suggest testing after 
discussion of pros and cons with the patient. 
One of the main concerns over PSA screening is the possible over diagnosis of 
prostate cancer.  Prostate cancer is very common in men and estimated to be present in 
15% to 30% of men over age 50.48  While many of these tumours would be classified as 
adenocarcinoma and be considered malignant, many would have low potential for growth 
and metastasis.48  In the US alone, it has been estimated from the National Health and 
Nutrition Survey and data from the PLCO trial that 1.6 million men aged 62 to 85 have a 
PSA level below 4.0ng/ml and harbor prostate cancer.49  Given that there is a lifetime risk 
of 18% for being diagnosed with cancer, but a 3% lifetime risk of dying from it, the 
potential pool of cases that do not require either diagnosis or treatment is considerable.50  
Jones suggests that the term “over diagnosis” is in fact incorrect.51  The literal 
definition of over diagnosis would be diagnosing more cases than actually exist, which is 
not the issue.  The issue is one of “over detection”.  Given it is hard to know which cases 
require treatment to prevent death from those that do not, means many men will be 
treated needlessly.  The clinically relevant cases need to be found, but since we don’t 
know which those are, the approach has been to find all of them.  So over detection leads 
to over treatment and additional anxiety in men.51, 52  The link between detection and 
treatment needs to be examined thoroughly.  Detection and treatment are very different 
processes.  After detection, in many cases the prudent approach might be to use 
surveillance where there is low potential for growth or metastasis.  Unfortunately many 
men just end up in treatment due to medical-legal fears of physicians and the attitude of 
men, who once diagnosed with cancer want it removed regardless.51  Surveillance, while 
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legitimate and useful, is also not an easy concept for the general population to understand 
given a new diagnosis of cancer.52 
Over detection will apparently remain an issue in Canada for some time.  Although 
the Canadian Task Force on Preventive Health Care in Canada recommends against 
routine PSA screening for asymptomatic men,17 the Canadian Urologic Association and 
the Prostate Cancer Alliance recommend screening only after a discussion of the pros and 
cons with patients.50  Regardless, surveys in Canada reveal that half of Canadian men 
have reported ever having a PSA test.50  This is not unique to Canada, the same over 
detection concern exists elsewhere outside of North America as well.53 
Although over detection is a concern and given that it is not known which prostate 
cancers would result in death, under diagnosis has also been suggested as a problem.  
Graif and colleagues conducted a study of tumour characteristics and concluded that 
under diagnosis was more common than over diagnosis.54  By lowering the PSA cutoff 
from 4.0ng/ml to 2.5ng/ml, under diagnosis was reduced from 30% to 26%, while over 
diagnosis increased from 1.3% to 7.1%.  This was also reported in another study looking 
strictly at tumour characteristics as the foundation of their definitions of over and under 
diagnosis, and concluded that under diagnosis was more common.55  Both studies were 
based in urology clinics.  While tumour characteristics are important, the true test of 
under diagnosis and over diagnosis would be knowledge of deaths from prostate cancer 
that could have been prevented and non prostate cancer deaths in men who were 
unnecessarily treated, respectively. 
Screening for prostate cancer nevertheless is fairly entrenched in Canada.  A 
survey in Quebec showed that 35% of men 50 to 69 years of age reported having a PSA 
test, even though there is a lack of definitive proof of benefit.56  The same survey showed 
that only 17% of men ever had a fecal occult blood test, even though the evidence shows 
that colorectal cancer screening is beneficial.  The prevailing notion again is that 
regardless of proof of mortality benefit, many physicians and the public simply just 
believe the PSA screening is saving lives.57 
Refinements are already being proposed for how screening should be conducted 
even in the absence of definitive proof of benefit.  Roobol and Schroder looked at the 
screening interval in two arms of the ERSPC trial comparing two- and four-year intervals 
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between PSA screens.  As expected more interval cancers developed using the four-year 
screening interval but these were mostly considered non aggressive based on tumour 
characteristics.  Otherwise, there was little difference between cancer detection rates 
using two- or four-year intervals.58  This result is potentially important given in the US, 
screening is largely done annually.  Crawford debated this result, not convinced that two- 
or four-year intervals should be used instead of the annual frequency currently promoted 
in the US.57  He points out that there was no randomization of men to either two or four 
years in the ERSPC trial, but that this was just a comparison of two different study 
countries that happened to choose different screening frequencies.  At the same time he 
also acknowledged regardless what interval is used; there is no trial evidence of any 
benefit at this point in time for prostate cancer screening. 
Given significant screening levels in North America, much has been written about 
how to improve the sensitivity and specificity of PSA testing.  Thompson et al showed 
that to find the aggressive cancers early in younger men and to improve sensitivity to 
80%, the cutoff for normal would have to be 1.1ng/ml.59  Their analysis was based on 
men 55 and over who had a total PSA of 3.0ng/ml or less, so a very select group not 
likely representative of the general population.  Changing the cutoff to such a low level 
would potentially find more of the aggressive cancers at early stages, but the over 
detection would be considerable.  In the end, the medical community needs to realize 
there is no “normal” PSA level.  It is a continuous marker that can exist at any level.  As 
it rises, risk of cancer rises.  At this point, it is very important that patients and physicians 
work together and discuss very carefully the issues about PSA screening and follow-up 
before deciding to proceed.28, 59  
3.2 PSA Test Use in Populations 
Not a lot is known about the extent to which the PSA test is used in populations.  
How frequent is testing in populations, what are the demographic characteristics of the 
men who are being tested, how close is actual practice to the recommendations that do 
exist, how has testing changed over time as PSA has become more entrenched in clinical 
practice, and how do PSA test results distribute in the population?  A number of studies 
have investigated the use of PSA tests trying to answer these questions. 
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An investigation of the National Ambulatory Medical Care Survey, a 
representative sample of patient visits to primary care providers in the United States, 
compared PSA use among men 35 years of age and older from 1995 to 2004.60  
Physicians ordering a PSA test for all types of visits increased from 4.7% to 7% over the 
time period.  For visits that were general examinations, ordering the PSA test increased 
from 11.2% in 1995 to 32.3% in 2004.  PSA testing was found to increase in all men, but 
more dramatically in African Americans and in young men 35 to 49 years of age.  
Veteran Affairs data from the US was also used to investigate PSA use among 
older men aged 70 years and over who had limited life expectancy.61  A large sample of 
almost 600,000 men from 2002 and 2003 was included in the analysis.  Fifty-six percent 
of men were found to have had a PSA test. PSA testing rates did decline with increasing 
age but did not decline appreciably with worsening health.  For men over 85 years of age, 
34% in good health had a PSA test, while 36% in poor health were tested.  Regardless, no 
recommendations anywhere suggest PSA testing over 75 years of age, so testing over 85 
years of age should be significantly lower than what is practiced among Veteran Affairs.  
In Iowa, practice patterns for prostate cancer screening were investigated by 
mailing a survey to all physicians who care for older men.  The response to the survey 
was 32%.  Of those who responded, most general practitioners and urologists replied they 
stop screening at age 80.  It was also found in this research that with increasing age, PSA 
use declined, but still a group of men over 80 years of age were tested.62  In another Iowa 
study based out of a urology setting 5.7% of men over 75 years of age had a PSA test.63  
Konety et al concluded that patients and providers both require education to be more 
selective about testing men over age 75 to minimize health care costs and unnecessary 
treatments. 
Self reports of PSA use are sometimes used to get prevalence of PSA testing in 
populations.  Chan et al investigated self reports of men attending two different outpatient 
clinics asking whether they had a PSA test or not.64  The self report was compared to 
actual records for sensitivity and concordance.  At both clinics, the sensitivity of self 
report compared to actual PSA use was only about 65%.  Concordance at the two clinics 
was 65% and 88%.  Results from such self report studies likely need to be interpreted 
carefully as in many cases, men are not aware they even had a PSA test.  
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A hospital-based analysis in Italy extracted records from the lab that served an area 
of 270,000.  The study looked at PSA testing patterns for the period 2002 – 2007.  They 
found many men (18%) over 75 years of age had a PSA test and as well, men under 40 
were tested.  Most tests were ordered by general practitioners.65 
Chun et al investigated the distribution of total PSA test results and the fPSA in 
healthy volunteers with no evidence of prostate cancer.66  Age-specific median PSA 
levels were determined.  In the youngest age group, 40-49, the median total PSA was 
0.7ng/ml and the fPSA ratio was 28%.  The median total PSA increased with age group, 
to a median of 1.8ng/ml for the 70-79 age group.  The fPSA ratio did not fluctuate very 
much by age group and overall was 25%.  If the threshold for biopsy was lowered from 
4.0ng/ml to 2.5ng/ml, 20% of men would require a biopsy.  If the fPSA ratio threshold 
for biopsy was less than 25%, half of the men would require a biopsy.  If the fPSA ratio 
threshold is lowered to less than 15%, then only 15% of men would require a biopsy.  
In Canada, questions about cancer screening behaviour are included in the 
Canadian Community Health Survey.  From this survey, 50% of Canadian men over 50 
years of age have indicated ever having a PSA test.67  As indicated previously, self report 
estimates of PSA use are likely to be underestimated.  Given national guidelines do not 
support prostate cancer screening; it is nevertheless commonly done in Canada. 
3.3 Improving PSA Testing Performance 
Different biomarkers have been investigated for over 20 years, but so far none 
have been as good as PSA for the detection of prostate cancer.68  The struggle is to find 
specific prostate cancers that can be treated and death from prostate cancer can be 
prevented.  PSA is generally good at finding advanced cancers but not all high PSA 
levels means that there is cancer.  As well, a low PSA level does not mean cancer is not 
present.15  Men with benign prostate disease have been shown to have higher PSA levels 
compared to some men who have and do not have cancer; as well, younger and older men 
with benign disease have been shown to have elevated PSA levels compared to men with 
no benign disease.69  Although the cutoff most often used for further investigation leading 
to biopsy is 4.0ng/ml, there really is no cutoff point where you can be absolutely sure 
cancer is not present.15, 59  A number of refinements have been suggested to improve the 
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performance of PSA testing such as PSA velocity, free PSA, age adjusted PSA levels, 
and PSA density.68    
PSA velocity refers to the increase in total PSA over time.  Increase could be 
absolute or relative and relevant time periods need to be established.  In general, a fast 
rising PSA would be more indicative of cancer.  One study comparing cases of prostate 
cancer to a screened group showed that for men with cancer, PSA velocity of 2.0ng/ml 
per year was associated with greater risk of death.70  
Age-specific reference ranges have been used for some time now and are 
commonly used in many urology clinics, especially in North America.  Given PSA rises 
with age as does the risk of prostate cancer, it seems natural to have age-specific ranges 
for further investigation.  Age-specific ranges are now being adopted increasingly outside 
of the United States, such as the United Kingdom.71  More recently, it has been identified 
that race plays a role in the distribution of PSA in non caucasian populations, resulting in 
the development of new age-specific reference ranges that are also race specific.72, 73  
Regardless, no level at any age provides anything close to 100% sensitivity and 
specificity. 
Determining the amount of unbound PSA, or free-PSA in serum has shown to be 
more discriminating at detecting cancer.74  The free-PSA ratio (fPSA ratio) is calculated 
as the percentage of free-to-total PSA.  Ratios less than 20% have been shown to be more 
indicative of cancer while ratios greater than 20% more indicative of benign disease.  As 
with total PSA, there is overlap between the two regions.  Originally the fPSA ratio was 
investigated in the diagnostic grey zone of 4.0ng/ml to 10.0ng/ml because of the 
considerable overlap of benign and malignant disease in that range.  A cost effectiveness 
analysis done in Spain showed that using the fPSA ratio prior to TRUS guided biopsy 
was the most cost effective approach to cancer detection, however the effectiveness was 
sensitive to the cost of the fPSA test and cancer prevalence.74  As well, this study was in a 
urology clinic setting, so men involved were already pre selected to attend the clinic 
because of existing symptoms or conditions such as BPH.   
More recently, research has focused on using the fPSA outside the 4.0ng/ml to 
10.0ng/ml range and at outcomes at different ratios other than 20%.  Pelzer et al used 
screening volunteers who had total PSA levels in the 2.6ng/ml to 10.0ng/ml range.  
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Biopsies were used if the total PSA was outside age-specific reference ranges.75  Prostate 
cancer detection was then calculated at different ratios, 1-9%, 10-14%, 15-18% and 
>18%, and at two ranges of total PSA (2.6ng/ml to 4.0ng/ml and 4.1ng/ml to 10.0ng/ml).  
They found significant differences in cancer detection between the two ranges of total 
PSA with higher detection in the 4.1ng/ml to 10.0ng/ml range.  This would be expected 
given higher total PSA conveys more risk.  When the fPSA ratios were used, the cancer 
detection was found to be greater in men with a ratio less than 15% between the two 
groups of total PSA.  There was no difference when fPSA ratios greater than 15% were 
used.  A study using frozen sections from the Physicians Health Study and using Receiver 
Operating characteristics curves showed that combined PSA and fPSA conveyed little 
improvement in cancer detection or specificity, except for total PSA under 4.0ng/ml, 
where there showed improvement in specificity of total PSA alone and without losing 
cancer detection.76 
In a meta analysis of the diagnostic performance of fPSA and the decision to 
biopsy, Receiver Operating characteristics curves were again used for all fPSA ratios in 
the 4.0ng/ml to 10.0ng/ml range of total PSA.14  Forty-one studies were included on some 
19,000 subjects.  The 20% fPSA ratio cutoff produced a sensitivity of 93% with only 
23% specificity.  fPSA was concluded to only be worthwhile in this range at more 
extreme values of fPSA ratios, under 10%, consistent with other findings that in the 
diagnostic grey zone of 4.0ng/ml to 10.0ng/ml, the fPSA ratio might need to be lower 
than 20%. 
3.4 Outcomes of Screening with PSA 
There is significant PSA screening done around the world in the absence of proof 
of its benefit.  Not surprisingly, a fair amount has been written about outcomes of 
screening and or the impact of this activity on tumour characteristics and mortality.  In 
the city of Tyrol Austria, the mortality from prostate cancer was shown to have dropped 
more than the rest of Austria after instituting a controlled screening and treatment 
program.  The program began in 1988, and offered PSA testing free of charge to all men 
45 to 75 years of age.77  Eighty-six percent of men had at least one PSA test in a 12 year 
period.  While the prostate cancer mortality rate dropped in the rest of Austria, the 
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decrease was significantly greater in Tyrol, which was attributed to screening, down 
staging of disease, and as well controlled treatment.78 
Stephens, Trotter, and Martin investigated mortality in the UK for the period  
1992 - 2004 and found that there was a larger decline in men aged 55 to 74.79  Treatments 
also changed during this time period, with more men having radical surgery and hormone 
therapy for their cancer treatment.  The decline in mortality however pre-dated the 
widespread use of PSA testing and to some degree the increase in surgery.  The observed 
declines were attributed to diagnosis of earlier stage disease and use of androgen 
suppression therapy that may have prolonged survival. 
Case control studies have been used to investigate mortality benefit from PSA 
testing as well.  In New Jersey, men who died of prostate cancer were matched to live 
controls without metastatic disease on age, race, and time of exposure to PSA.  The 
screening histories were determined for all cases and controls and no difference was 
found in screening histories.80  Another case control study in Washington State matched 
new prostate cancer cases (diagnosed 1993-1996) on age with controls found through 
random digit dialing.81  Self reported data about screening was obtained and follow-up 
continued to 2007.  Fewer men with PSA testing had a prostate cancer death.  Although 
the study suggested mortality benefit from PSA screening, the self reporting of 
information from participants makes for cautious interpretation. 
Preliminary results from the ERSPC have been published looking at surrogate 
measures of screening effect such as reductions in diagnosis of metastatic disease in men 
screened.82  In Sweden after 10 years of screening, there was a significant reduction of 
49% in the diagnosis of metastatic disease, but it came with a 1.8 fold increase in cancer 
detection.  The assumption is that diagnosing less advanced disease will result in lower 
mortality.  While this remains to be proven, the issue of over detection and the costs 
associated with it need to be taken into account. 
One of the key early measures of screening effect when screening intensity 
increases is an observed shift stage distribution.  If cancer screening is going to be 
effective, disease needs to be diagnosed at earlier stages where treatment and prognosis 
are significantly better.  Since mortality benefit has not yet been established for prostate 
cancer screening, stage shift has been investigated as evidence of a precursor indicator of 
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future mortality decreases.  In Japan, a mass screening program was instituted in the 
Otokuni District for men 55 years of age and older since 1995.  Men who had total PSA 
test results in the 4.0ng/ml to 10.0ng/ml range had a PSA density determined as the 
second line test.  After 10 years of serial testing, there was a 17% increase in organ 
confined cancer and a 12% decrease in advanced cancer in the second five-year period 
compared to the first five years.83   
Similar findings have been witnessed in many other jurisdictions.  Stage migration 
to more organ confined disease was found to coincide with the PSA testing era in Ohio.84  
This migration then slowed in the later time period of study, which would be expected as 
part of a screening effect.  A similar pattern occurred in Italy over a 15 year period of 
study, where organ confined disease became more prevalent in the PSA era.85  Both 
studies were based on tissue samples from prostatectomy surgeries however, and as such 
are not reflective of stage migration in the entire population of cases. Surgery would be 
limited to men generally under 70 years of age with favourable prognosis.  
A population-based analysis of tumour characteristics covering 1996 to 2005 
occurred in Sweden.86  Stage migration was seen with more organ confined disease and 
smaller tumours becoming more common.  The age-standardized incidence rate of cases 
with metastasis at diagnosis also dropped.  There was considerable geographic variation 
around the country in the age-standardized rates of small tumours and in the median age 
at diagnosis, which was attributed to different PSA testing intensity in those regions. 
Aside from stage migration, mortality benefit will only be possible if the effects of 
treatment make any difference in the outcomes of screen detected cancers.  Survival 
improvements may indicate potential mortality benefits but issues associated with lead 
time bias and over detection from screening make interpretations difficult.  Parker et al 
investigated the natural history of screen-detected prostate cancer and effect of treatment 
on survival using data from the UK.15  The model developed indicated a mortality benefit 
from radical treatment for men 55-59 years of age if their Gleason score was greater than 
7, but there was modest improvement for Gleason scores 7 and no benefit for Gleason 
scores less than 7.  While the result makes sense that benefit would result in cases with 
more aggressive tumours, it does not mirror what is actually happening in current practice 
patterns.15 
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3.5 Informed Consent and Decision Making for PSA Testing 
Informed decision making about whether to proceed with a procedure or test is 
not a new concept in the provision of heath care services.  As this subject relates 
specifically to prostate cancer screening however, a whole new field of study has 
emerged.  Prior to 2000, a search of PubMed using the terms “decision” and “prostate 
cancer screening” produced 32 article titles.87  For the period 2000 to end of 2007, the 
same search reveals almost three times as many articles, 86.88   
The increase in research about informed decision making for prostate cancer 
screening is understandable.  First, since the screening trial evidence of mortality benefit 
is not in yet, physicians need to be quite careful about proceeding with testing men with 
PSA where there are so many pros, cons, and controversies associated with it.  As well, 
many of the guidelines that exist, even those that promote PSA screening, advise 
physicians to council patients individually about the benefits and risks.89 
In the US, the American College of Preventive Medicine recently conducted a 
review of literature about PSA testing for screening.90  After review they determined 
there was insufficient evidence to recommend routine population-based screening with 
PSA for prostate cancer.  Their official position was that men at higher risk, African 
Americans, and men with family history of prostate cancer, should be offered information 
about the potential benefits and risks of PSA testing so that informed decisions to proceed 
can be made.   
The American Cancer Society on the other hand recommends that physicians offer 
the PSA test annually to men over age 50 that have at least 10 years of life expectancy.  
They also state that men with higher risk should begin testing at 45 or even 40 depending 
on their risk level.  At the same time, their recommendations say that no organization in 
the US recommends routine testing for prostate cancer and they reference the American 
College of Preventive Medicine recommendations noted above.91  Finally, the ACS also 
recommend that health care professionals discuss the benefits and limitations of prostate 
cancer screening with men to allow for informed decision making at their yearly 
checkups.  
The media plays a large role in influencing decision making, especially in the 
United States.  A random digit dialing survey conducted in the US found that celebrity 
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endorsements played a role in people’s decision about screening using mammography, 
sigmoidoscopy or colonoscopy, and PSA.92  The survey had a good response rate of 72% 
among those known to be eligible and 51% among those who were possibly eligible. 
Most respondents said they had seen celebrity endorsements about all three modes of 
screening and 31% of the men said they were more likely to undergo PSA testing after 
seeing the endorsement.  There is likely a similar effect in Canada, given much of our 
media, especially television, is American based. 
These endorsements are certainly not unique to the United States.  In Australia, 
Steginga and Gardiner wrote about the media enthusiasm about prostate cancer 
screening.93  They point out that even in the absence of mortality benefit, there should be 
no surprise about the promotion of screening given there are as many prostate cancer 
cases diagnosed and deaths as there are from breast cancer in the country.  Since no 
national public health strategy is in place to date, the door is open for advocacy groups to 
promote screening to the media, who are more than willing to accommodate.   
Steginga and Gardiner point out that the prostate cancer screening debate has 
evolved to include very polarized views, where as constructive debate has often been 
curtailed.93  They point out that differentiation between PSA screening of all men and 
testing after informed consent as suggested by Australian cancer control agencies is very 
important.  Decision aids already exist in numerous formats that can assist men’s 
understanding about prostate cancer, enabling them to make informed decisions.  These 
decision aids however have also been found to make little difference on actual testing 
behaviour.  The informed decision making process needs to be incorporated into primary 
care, the point where the decision to test is made.93  
In Canada, a mailed survey was conducted among family physicians in five 
provinces.94  The physicians were asked about how patient expectations influences their 
decision to order cancer screening tests.  The response rate was good at 62%.  Physicians 
most likely to order tests for routine cancer screening believed that screening was 
recommended, while physicians least likely to order the same tests did not believe 
screening was recommended.  However patient expectations or anxiety increased 
screening among physicians who did not believe routine screening was recommended.  
The chance that a PSA test was ordered among these physicians went from 28% to 54% 
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in the presence of patient expectations or anxiety.  In the absence of patient anxiety or 
expectation, the physician belief about screening was the dominant factor predicting 
ordering of screening tests. 
The physician-patient relationship is a critical one for informed decision making 
about the decision to have PSA screening.95  Fenton and colleagues analyzed the 
screening activity among enrollees of a managed health plan in Washington State to see 
how important the preventive health examination was in determining screening activity.96  
After adjustment for demographics, existing comorbidity and other factors, men who 
received a preventive health exam were three times more likely to have a PSA test for 
screening then men with no such exam.   
Since physician opinions play a big role in the decision making process, it is very 
important that they put aside their personal beliefs as much as possible when counseling 
patients.  Physicians who support PSA screening need to acknowledge the limitations and 
potential risks associated with testing.  Conversely, physicians who do not believe in PSA 
screening need to inform patients of the potential benefits.  Only with full disclosure can 
a patient make an informed decision, regardless of the physician preference.97 
Katz and Sisler provide an excellent synopsis on the issue of PSA screening from 
the family physician point of view in Canada.98  There is a lot of pressure and 
requirement to inform men about all issues related to PSA testing because we are in a 
“middle of the road” state on the PSA issue.  But informing the patient of all potential 
limitations and benefits is very time consuming.  They point out the office visit might not 
do anything to persuade men either way if they have their own beliefs based on fear of 
cancer, positive or negative anecdotes from family or friends, and the influence of 
celebrity endorsements in the media.  As well, prostate cancer advocacy groups promote 
screening with the goal to find all cancers but the more important outcome should be to 
advocate for those activities that will result in reduction in mortality, which may or may 
not happen from just finding all cancers.  As well, Katz and Sisler state that the public in 
general does not trust statistics, which can be interpreted differently or made to look one 
way or the other.  They also admit it is hard for physicians to put their own beliefs aside.  
Older male family physicians for example, may be more inclined to support prostate 
cancer screening.   
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Advocacy groups also promote more counseling time with men about PSA testing.  
However, the reality for physicians is that another 20 minutes of counseling, in a fee-for-
service environment such as Canada, does not make economic sense for the physician.  It 
is easier and better time management to just do the test in the 2 minutes it takes instead of 
spending 20 minutes trying to inform a patient of all the issues.  In the end, men who 
want screening and believe in it or those who do not want it are not likely going to be 
convinced otherwise.98  Family physicians time would be better spent counseling those 
men who are unsure and do not have a fixed opinion either way.  For men who do have 
their own opinions and expectations, all the physician should do is let them know the 
consequences either doing the test or not.98 
Hewitson and Austoker conducted a literature review on the subject of informed 
decision making, patient information, and the psychosocial impact of PSA testing for 
prostate cancer.99  Their review found 24 organizations that had recommendations about 
prostate cancer screening and only three that endorsed population-based screening; the 
American Urologic Association, the Canadian Urologic Association, and the American 
Cancer Society.  Regardless of recommendations, they found that men now are more 
often asking for the PSA test.  Publicity about testing and prostate cancer has raised 
public awareness and helped shape public opinion.  As well, it appears that people in 
general have a belief that prostate cancer can be cured if found early.   
An interesting difference has been reported in relation to anxiety about PSA testing 
in men for prostate cancer compared to women tested with mammography for breast 
cancer.  It has been shown that men have low anxiety levels about PSA testing.99  
Carlsson et al found that men who were having PSA tests had low anxiety levels while 
having the test, while waiting for test results, and even while waiting for biopsy results.100 
Hewitson and Austoker’s review found that there is much more emphasis now on 
providing men with balance and relevant information on the subject of prostate cancer 
screening, to allow for informed decision making.  There is evidence that providing 
information is beneficial, but there is very little evidence about what information to 
supply and even what the general public is able to understand considering the complexity 
of issues related to cancer screening.99  Key questions remain unresolved about what 
information health professionals believe men require, how to present it to them, and what 
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they are able to understand.  As well, it is important to know what the key factors and 
beliefs are for men that influence their decision making.  
Three primary methods used for informing men about PSA testing and screening 
were identified by Hewitson and Austoker; verbal, written, and video.  Verbal 
communication between men and health professionals has been found to increase men’s 
knowledge about prostate cancer screening in general, and as a result, interest in PSA 
testing appears to have decreased in these men.  This method however requires a lot of 
physician time.  Providing written documentation to men has also been shown to increase 
their knowledge on the subject.  Studies however have not had consistent findings on 
outcomes resulting from written communication.  Some have found that interest in PSA 
testing decreased in men after reviewing written information on the issues, while other 
studies found it made no difference in testing patterns.  One study found that PSA testing 
increased significantly with a combination of written information and provision of PSA 
testing that was free of charge.  Using video to present information was also found to be 
successful at increasing knowledge in general, and as a result interest in PSA decreased in 
men. 
Overall, knowledge about prostate cancer screening increased in men no matter 
what method was used to provide the information.  In general, it was found that interest 
in screening decreases once the men are informed.  It is not known what factors make 
men change their minds, knowledge about the risk of prostate cancer, the performance of 
the PSA test, issues about diagnostics or treatment related factors.  The most consistent 
finding is that testing is much higher in men when the PSA test is available free of 
charge.  As well, for men who were seeking out screening, providing information made 
no difference in their decision to be tested.101 
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4.0 ANALYTIC PLAN 
To support the project goals for each of the three projects mentioned in Section 
2.0 required consideration of the analytic methods and associated data requirements.  
Projects 1 and 2 were largely focused on the use of the PSA test in Saskatchewan.  The 
hypothesis for Project 1 was that there is significant use of the PSA test in the population 
and that without clear recommendations for its use, considerable variation would exist in 
the province among men tested by age group, frequency of testing, and geographic 
location.  As well, it is unknown how PSA test results distribute in a population, although 
they would be expected to be age-related.  The primary interest was how these factors 
were distributed amongst men who did not already have prostate cancer.  
To investigate the hypotheses for Project 1 required population-based PSA data as 
much as possible.  The data also needed to be at the individual level including 
demographic information to describe the men who were tested.  As well, knowledge of 
their cancer status and dates of diagnosis would be necessary to estimate screening levels 
among men with no previous prostate cancer at the time of their PSA tests.   
Requirements for Project 2 were similar to those of Project 1 with the added 
requirement for biopsy information.  The hypothesis for Project 2 was that knowledge of 
the free-PSA ratio would impact the biopsy rate and the cancer detection rate for men 
who did not have a previous prostate cancer diagnosis and who had a total PSA between 
4.0ng/ml to 10.0ng./ml.  The underlying assumption was that knowledge of the free-PSA 
ratio would better discriminate risk of cancer among these men.  If the assumption was 
true, biopsy rates would either drop with either no change or an increase in cancer 
detection, or biopsy rates would remain stable but with increased cancer detection 
resulting from more “appropriate” follow-up.   
Project 3 was focused on the impacts of PSA testing on cancer diagnosis, tumour 
characteristics, and changes in clinical management of prostate cancer that may have 
been brought about by years of PSA testing.  The assumption being that given free 
availability of PSA testing, screening is commonly practiced in Saskatchewan.  If so, the 
35 
hypothesis would be that in the presence of effective screening, cancer detected would 
shift to more organ-confined, early stage cases at time of diagnosis.  As well, in the 
presence of screening it would be expected that treatment patterns would change to 
reflect a higher percentage of early stage cases.  More aggressive treatment options are 
available to men with early stage disease when cure is still a possibility.  Therefore the 
hypothesis was that with a stage shift, clinical management of prostate cancer would also 
shift to more radical treatments in Saskatchewan.  
Considerable data requirements were necessary to investigate the hypotheses 
mentioned above and in Section 4.0.  The sources of data and record linkages required are 
shown in the schematic diagram in Figure 4.1.  Projects 1 and 2 required electronic data 
from the two labs in Saskatchewan capable of analyzing PSA samples.  This data had to 
be linked to data from the Cancer Registry to identify men who had prostate cancer prior 
to their PSA tests.  As well, biopsy data was obtained from pathology departments to 
ensure there were no missing biopsies performed outside of the fee-for-service structure.  
The information had to be sent to Saskatchewan Health for further database links to 
secure demographic information of men tested.  As well, billing data was used to secure 
more biopsy information for procedures that were done through fee-for-service.  
Data required for Project 3 was exclusively supported by the Cancer Registry and 
an extensive chart review that was conducted.  As shown in Figure 4.1, the Registry data 
linked to the PSA data prior to being sent to the Health Department to support Projects 1 
and 2.  This linkage occurred at two levels, one an extensive linkage of Registry data 
including cancer data from 1970 to 2002 was used so men with previous prostate cancer 
could be identified in the PSA data.  The chart review data covered a shorter portion of 
time but included more information about tumour characteristics that could be useful to 
Projects 1 and 2 as well.  
The Saskatchewan Cancer Registry is a population-based registry that has been in 
existence since 1932.  The Registry is considered complete since 1945 and electronic 
records are available since 1968.  The PSA data required for the study came from the 
Pasqua Hospital in Regina, Saskatchewan, Canada, and the Royal University Hospital in 
Saskatoon, Saskatchewan, Canada.  Linkage of these files was done by the provincial 
health department, Saskatchewan Health, by using a unique person identifier common in  
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Figure 4.1 Data Sources and Record Linkages 
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all data sets, the Health Services Number (HSN).  The linkage process was done offsite, 
at Saskatchewan Health and the files returned to the investigator for analysis with the 
original identifiers removed and new study numbers assigned to each record to preserve 
confidentiality of information.  
A detailed description of each data set follows.  Analytic methods were primarily 
descriptive in nature and are discussed following the description of the data. 
4.1 Saskatchewan Cancer Registry 
The Saskatchewan Cancer Registry (SCR), which has been in operation since 
1932, is one of the oldest population-based cancer registries in the world.  Saskatchewan 
has a stable population of about one million people.  In Saskatchewan, cancer is a 
reportable disease.  The SCR prospectively gathers information on all Saskatchewan 
residents diagnosed with invasive and in situ cancers, and has an estimated 99% 
completeness of case ascertainment for all sites combined.102 
Information contained in the registry includes patient age, sex, date of diagnosis, 
dates of follow-up and status at last follow-up.  The anatomic site and morphologic type 
of each cancer are coded according to the International Classification of Diseases - 
Oncology (ICD-O) system.103  For prostate cancer, 93.3% of registered cases since 1970 
were microscopically confirmed, and for the period 1990 to 1994, this value was 
97.1%.102,104-107  The SCR contains some information on extent of disease and on cancer-
directed treatment, but this information is of variable quality and completeness across 
different cancer sites and over time.  Prostate cancer was one of the sites missing this 
additional information. 
Information on deaths in Saskatchewan residents is reported to the Registry on a 
regular basis by the provincial Department of Vital Statistics, which codes cause of death 
according to the ICD-10 classification.108  This information is linked to registered 
patients. 
Follow-up information on all surviving cancer patients in Saskatchewan is 
obtained by one of two processes.  Active follow-up consists of regular visits with a 
physician at one of the two provincial cancer centres.  The frequency and duration of 
these visits varies according to the type of cancer, its status, and the ability of the patient 
to come to the clinic for regular appointments.  After completion of active follow-up, 
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patients were referred back to the family physician or referring specialist, to whom 
annual letters are sent requesting up-to-date information on the patients’ status; this is 
known as passive follow-up, or “follow-up-by-mail”.  This passive follow-up was 
temporarily postponed in 2006 while the Saskatchewan Cancer Agency developed a new 
discharge policy.  To date, approximately 170,000 persons have been registered with the 
SCR, and only 2% have been lost to follow-up. 
As mentioned, prostate cancer cases in the SCR were missing important 
information.  There was very limited data about extent of disease (stage) and grade at 
time of diagnosis, and also limited data about method of diagnosis or first course of 
treatment.  To enhance the SCR’s ability to monitor the most common cancer site in the 
province, a large chart review was undertaken to collect additional information for 
prostate cancer cases for the period 1985 to 1999 as shown in Figure 4.1.  This chart 
review was supported by a grant from the Saskatchewan Cancer Agency and additionally, 
a follow-up grant to complete the work.  To date, nearly all prostate cancer charts for the 
time period 1985 to 2002 have been reviewed.    
In brief, health records technicians collected information from patient charts under 
the direction of Dr. David Skarsgard, a radiation oncologist with the Saskatchewan 
Cancer Agency at the time.  A document was created which summarized the rules for 
data collection.  It was continually updated throughout the review as new situations were 
encountered and new rules were developed so that subsequent cases would be dealt with 
similarly.  Error rates in the data were recorded as type I or type II.  Type I errors were 
those that could have a significant effect on interpretation of the results, e.g. incorrect 
stage, incorrect grade, incorrect first treatment etc.  Initially, the type I error rate was 
found to be about 5% when random audits were conducted.  After resolving errors, the 
type I rate lowered subsequently, so that overall the error rate in the data is believed to be 
less than 5%.  
Data collected in the review included clinical stage and grade at time of diagnosis.  
Clinical stage at diagnosis was assigned using information in the chart from as close as 
possible to the time of diagnosis, before any prostate cancer directed treatment.  Clinical 
stage just before treatment was assumed to be the same as at diagnosis, unless there was 
information in the chart suggesting otherwise.  Clinical stage was assigned using a 
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simplification of the American Urological Association (sAUA) staging system, A, B, C 
or D.109  Designation of substages within the AUA system (e.g. A1 vs. A2, B1 vs. B2) 
was felt to be impractical and inaccurate because of the variable amount of detail in 
charts. 
For the prostate cancer data in the SCR and in these research projects, stage A 
refers to clinically and radiologically occult cancer which was biopsy-proven (e.g. by a 
TURP or needle biopsy).  Stage B refers to clinically and/or radiologically detectable 
cancer which was confined to the prostate.  Possible descriptions suggesting stage B 
include a “firm or hard nodule” and ”focal or diffuse induration”, with no evidence of 
metastases.  A diffusely firm prostate without focal abnormalities and with no evidence 
of metastases could be consistent with either stage A or B, so the assigned stage took into 
account the physicians interpretation. 
Cancers with extracapsular and/or seminal vesicle involvement, without evidence 
of metastases were considered stage C.  The lateral margins of the gland were often 
described as being poorly defined.  Other adjectives that were assumed, unless otherwise 
stated, to describe stage C disease include “fixed”, “grossly irregular”, “locally 
advanced or extensive”, and a “diffusely rock-hard or a huge cancerous prostate”.  
Stage D refers to locally advanced disease that is beyond stage C (e.g. gross 
invasion of bladder or rectum).  It also includes regional (pelvic lymph node) and distant 
metastases.  Pathologic confirmation of metastases was not required, but the treating 
physician had to have concluded on clinical and/or radiologic grounds that metastases 
were present and to have managed the patient accordingly. 
Gleason score was recorded as a single number (ranging from 2 to 10 out of 10), 
which represented the sum of the grades (from 1 to 5) of the first and second most 
prevalent histologic patterns in the specimen.  For the purposes of this analysis, the 
Gleason scores were group as well differentiated (Gleason 2 to 4), moderately well 
differentiated (Gleason 5 to 7) and poorly differentiated (Gleason 8 to 10) tumours.  
Date of diagnosis was defined as the date on which it was first decided that a 
patient had prostate cancer.  Usually that was the date on which histologic confirmation 
was obtained.  This date was already in the SCR but was confirmed during the review.  
However, if a patient was assumed on clinical and/or radiologic grounds to have prostate 
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cancer and was managed accordingly before tissue confirmation of cancer, then the date 
of diagnosis was recorded as the date on which the clinical diagnosis was first made.  
The method of diagnosis was recorded.  Possibilities included prostatic needle 
biopsy, transurethral resection of the prostate (TURP), radical prostatectomy, other 
biopsy (e.g. lymph node, bone marrow), and clinical/radiologic diagnosis.  When a 
patient had more than one diagnostic maneuver on the same day (e.g. TURP and needle 
biopsy), and both showed cancer, both methods were recorded.   
The chart review recorded the first prostate cancer-directed treatment, if any, 
which was received by a patient at any time after diagnosis.  Possible first treatments 
included radical prostatectomy, radical radiotherapy, hormonal treatment, and no 
identified treatment (by time of chart review).  A very small number of patients were 
treated initially with chemotherapy.  All the Saskatchewan Cancer Agency medical charts 
were reviewed and contained records of all radiotherapy and chemotherapy, all medical 
or surgical hormonal treatment, and all radical prostatectomies that were given or 
performed in the province.  Even patients who received some or all of their treatment out 
of the province usually had this treatment referred to in the Saskatchewan Cancer 
Agency’s clinical notes. 
A file was generated of all prostate cancer cases diagnosed in Saskatchewan 
residents for the years 1985 to 2002.  Information obtained from the SCR included date 
of diagnosis, date of death, cause of death, the health services number (identification 
number), and morphology.  This data was supplemented with additional data elements 
from the prostate cancer chart review and included stage at diagnosis, grade, diagnostic 
method, first course of treatment, and all the associated dates.  The two sources were 
linked using the HSN creating one complete file of all the prostate cancer cases.  This 
combined data from the Registry and the chart review provided the necessary information 
to support Project 3.    
4.2 PSA Lab Data 
An advantage of studying PSA use in Saskatchewan is that only two labs are 
currently equipped to analyze serum samples for the whole population (Figure 4.1).  As 
described earlier, the Pasqua Hospital lab in Regina had electronic records beginning in 
May 1997.  Most of the lab data files were archived and had to be de-archived to extract 
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the data.  The Royal University Hospital in Saskatoon only had electronic records 
beginning in 2001.  However, the majority of community-based PSA testing was done at 
the Pasqua Hospital for this time period.  PSA records were obtained for the time period 
May 1997 to the end of 2001. 
Records were obtained from the labs that included the following data: date the 
serum sample was taken, total PSA test result (ng/ml), patient HSN, patient first and last 
name, patient birth date, first and last name of the ordering physician and from the Pasqua 
Hospital, the amount of free unbound PSA (for tests done after October 1999 where the 
total PSA was between 4.0ng/ml to 10.0ng/ml).   
This extraction generated a file containing over 291,000 records.  The files 
contained many duplicate records which had to be resolved.  This was a very involved 
process because of the possibility that men could have more than one PSA test on the 
same day; therefore records had to be checked for all data elements to determine if it was 
a true duplicate.  As well, the Pasqua lab generated four separate records in the data 
whenever a reflex test was done to determine the free-PSA amount.  These records all 
had to be reconciled into a single record that contained the total PSA, the free-PSA 
amount and the ratio for each case.  
After the data clean-up, there were still over 230,000 records in the data file 
representing about 107,000 different men.  Many men had more than one PSA test during 
the study period, many with five or more occurrences.  To assist with analysis a count 
was assigned to each record representing the number of times each man was in the date 
set.  As well, a sequence number was put on each record representing the chronologic 
order of each test for each man.  For example, if a man had six PSA tests, then the count 
on each of his records was six and a sequence number ranging from one to six was put on 
each record based on the earliest PSA date to the latest.  
Age was calculated for each record in the PSA file as the age at the time of the 
PSA test.  The free-PSA ratio was calculated as the free-PSA amount divided by the total 
PSA level and converted to a percentage.  The data file was then sent to Saskatchewan 
Health along with the previous prostate cancer file from the registry as indicated in 
Figure 4.1.  At Health, the identifier was removed from the file and unique study numbers 
42 
assigned to cases in the same manner as was done with the cancer file from the registry so 
the files could be linked.  
Prior to returning the files, Saskatchewan Health retrieved additional information 
for the PSA file.  The residence of each man at the time of their PSA test was added to 
the data set.  The province is divided into 13 health regions, and for each PSA record the 
health region was added.  As well, biopsy and TURP data was added for each case.  
These procedures during this time period were largely performed by urologists in the 
province.  Physicians bill Saskatchewan Health fee-for-service based on procedures they 
perform.  These procedures can be tracked and contain the date the procedure was done, 
the patient HSN, codes for the procedures performed, and a unique ID of the physician 
who did the procedure.  
Saskatchewan Health added additional information to each PSA record as follows.  
Each PSA record was linked by the HSN to the billing data.  If a follow-up procedure of 
interest (biopsy, TURP, physician visit) occurred in a man within a year after the PSA 
test and prior to a subsequent PSA test, then the data was included in the dataset.  
The cancer file and the PSA file were returned and all identifiers of patients were 
removed.  The study numbers were unique to men so linking the prostate cancer data to 
the PSA data was possible.  Saskatchewan Health also provided a list of all the physician 
specialties that occurred in the data.  The names were reviewed and a physician specialty 
was assigned to each PSA record.  Each PSA record was coded as being ordered by either 
a urologist, an oncologist, or a general practitioner.  There are not a lot of urologists in 
Saskatchewan so it was possible to review all the names and link a specialty to each 
record.  If the physician was not a urologist or oncologist, it was assumed to be a general 
practitioner.  This assumption would certainly not have been true in every case, as some 
other physician groups, such as internal medicine etc could have ordered a PSA test.  But 
review of the physician’s names revealed that the vast majority were GPs, after urologists 
and oncologists.    
Due to the identifiable nature of the data and the linkages required between 
datasets from numerous organizations, ethics approval was sought and provided by the 
Biomedical Research Ethics Review Board from the University of Saskatchewan (REB 
file # BMC 01-107, Certificate of Approval provided in Appendix 2).  Because of the 
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time it took to obtain data and approvals, extensions for the ethics approval were obtained 
as required until study completion.  As well, the data linkage at Saskatchewan Health had 
to receive internal approval from the Data Access Review Committee, which was granted 
albeit after significant time delays. 
This research was also supported by a grant from the Health Utilization and 
Research Commission (HSURC).  HSURC no longer exists as the organization changed 
and the granting portion became the Saskatchewan Health Research Foundation, who 
continued to support the grant.  The money from the grant was used to secure data from 
the organizations involved and cover the costs of the linkage.  
4.3 Methodology 
The analysis for the three projects was largely descriptive in nature and is further 
explained within each project chapter.  Denominators for all rates were from the Covered 
Population of Saskatchewan, an annual publication produced by Saskatchewan Health 
about population of Saskatchewan residents who are eligible for insured health services 
(and who therefore are assigned a HSN).110  The only people not included in the Covered 
Population are people under federal jurisdiction, such as prison inmates and members of 
the Federal armed forces or the Royal Canadian Mounted Police.   
The primary interest in the studies was to investigate the impact of PSA testing on 
the incidence of prostate cancer in Saskatchewan and to provide detailed information 
about how the PSA test is being used.  For much of the analysis, the interest was PSA 
testing in men without known prostate cancer.  Linking the prostate cancer file to the 
PSA file made it possible to see who had a PSA test after a diagnosis of cancer.  In much 
of the analysis, if the date of prostate cancer diagnosis was before the date of the PSA 
test, then these records could be eliminated from further analysis.  For this reason, and 
due to the survivorship of men with early stage prostate cancer, the prostate file included 
records dating as far back as 1970. 
The 1991 Canadian population was used for age standardization.  
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5.0  PROJECT 1.  WHAT HAPPENS WHEN PROSTATE SPECIFIC ANTIGEN 
TESTING IS AVAILABLE FREE OF CHARGE IN A POPULATION: THE 
SASKATCHEWAN EXPERIENCE 
5.1 Introduction 
Use of the prostate-specific antigen test has been the subject of much discourse 
over the past 15 years and still conjures significant debate.  The utility of the test as a 
screening tool remains a contentious one with different organizations and countries 
making different recommendations and taking different approaches with its use.  In 
Canada, screening for prostate cancer (PCa) in the general population is not currently 
endorsed; however each province has made their own decisions on the availability of the 
test, since the authority for provision of health services reside under provincial 
jurisdiction.   
In the province of Saskatchewan, PSA tests were introduced in 1990.  No 
restrictions were placed at that time, meaning every resident in the population was 
eligible for testing at no direct cost to the patient.  Most other provinces did not allow 
such widespread availability.  In all provinces now, the test is available for cancer follow-
up; in some provinces the test is available as a screening test but at the patients expense.  
Given the availability of the PSA test at no cost to patients, use of the PSA test in 
Saskatchewan increased dramatically from 1990, going from 600 tests in that year to 
48,000 tests by 1994 in a population of only one million, of which about 116,000 men 
were aged 50-79.  As was seen in most other industrialized societies, the age-adjusted 
incidence rate of prostate cancer in Saskatchewan increased significantly, from 104.4 per 
100,000 to 154.9 per 100,000 from 1990 to 1993.   
It is still not clear whether screening for prostate cancer using PSA provides any 
benefit to the men tested.  Questions about reductions in mortality from prostate cancer 
screening will hopefully be answered from the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial in the US or the European Randomized Study of Screening for 
Prostate Cancer.1, 2  Even in the absence of mortality benefit from screening trials, it is 
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apparent that screening for prostate cancer is fairly entrenched in many North American 
jurisdictions.  PSA testing has been ongoing for 18 years now in Saskatchewan but how 
this test is being used in men is not as well known.  Fundamental questions remain yet 
unanswered.  How are men being tested at the present time?  What age groups of men are 
being tested?  How often are tests done?  Are there geographic variations of testing in the 
population, and how are test results in the population distributed?  Who orders most of 
these tests?  These are some of the questions that need to be further examined.  
The purpose of this study was to provide a population-based descriptive 
epidemiologic perspective of PSA use in the province of Saskatchewan where the test is 
available at no cost to the patient.  The hypothesis is that PSA testing is widespread in 
Saskatchewan and that in the absence of clear guidelines, considerable variation exists in 
how the test is being used.  The goal was to investigate who was having PSA tests and 
how often.  The aims of the study were to estimate age-specific prevalence of PSA testing 
in men with no previous cancer, as well overall age-specific PSA use, investigate 
geographic differences of PSA test use, and determine the age-specific range of test 
results that actually occur in a population-based setting.   
5.2 Methods 
Saskatchewan has two labs that analyze PSA samples, the Pasqua Hospital lab 
(PH) in Regina and the Royal University Hospital (RUH) lab in Saskatoon.  Records 
were available at the PH lab going back to the fall of 1997. At the RUH, electronic 
records were only available beginning in 2001.  This study made use of individual PSA 
records for the period 1997 to 2001 from the Saskatchewan population. 
When the PSA test became available in Saskatchewan in 1990, the PH lab was the 
only one capable of doing the serum analysis.  Because of this, all PSA tests, whether for 
follow-up purposes in cancer patients or community-based tests from general 
practitioners, went to the PH lab exclusively.  After a few years, the RUH lab started to 
analyze blood samples for PSA, but their primary focus was to provide the service as a 
follow-up to cancer patients in the Saskatoon Health Region. 
In 1997 the PH lab began recording test results in electronic format.  Each serum 
sample had a requisition form associated with it indicating the physician who ordered the 
test, the patient’s name, and the patient Health Services Number.  The Health Services 
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Number is a unique number assigned to each resident of the province, which is to be used 
when interacting with the health care system.111  
The PH lab retrieved from its archive database all the PSA records from mid May 
of 1997 to the end of 2001.  The RUH lab did not have electronic records until the year 
2001.  All records were retrieved from these labs for the period 1997 to 2001 that were in 
electronic format.  For each record, the first and last name of the physician who ordered 
the PSA test, the first and last name of the patient who had the test, the patients Health 
Services Number, the date of the PSA test, and the total PSA value in ng/ml was 
provided. 
The PSA data between the two labs was merged into a single file with the same 
format.  Duplicate records defined as those that indicated the same date of the PSA test, 
same test result, from the same physician, for the same patient were eliminated.  A further 
reconciliation was done for the records from the PH lab.  This lab did an additional reflex 
analysis on every serum sample where the total PSA value was between 4.0 ng/ml and 
10.0 ng/ml.  If the total PSA was in this range, the same sample was automatically 
reanalyzed to determine the free-PSA ratio (amount of free (unbound) PSA in that 
sample).  This additional information was sent to the ordering physician along with a 
guideline for interpretation.  This process also generated an additional electronic record in 
the files.  For these cases, the data was converted to a single record containing the total 
PSA and fPSA amount so it could be interpreted as a single event.  The PH lab began this 
reflex testing process in the fall of 1999.  
At the same time a file was generated from Saskatchewan’s population-based 
provincial cancer registry.  The Health Services Number and diagnosis dates for all men 
diagnosed with prostate cancer for the years 1970 to the end of 2002 was obtained from 
the cancer registry.  This file was linked to the PSA file based on the patients Health 
Services Number that we had from the labs, so we would know whether the men tested 
with PSA had a prior prostate cancer diagnosis or not.  
Another goal was to analyze who was ordering the PSA tests.  There would be 
three main physician types ordering a PSA test in Saskatchewan, general practitioners, 
urologists, and oncologists.  Doctor name associated with each test was obtained and it 
was possible to identify by name, those who were urologists and oncologists in the 
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province, since the number of these physician specialties is relatively small and fairly 
stable.  It was assumed all other physicians to be general practitioners even though some 
could be general surgeons but these would be very few in comparison.      
To calculate prevalence rates in the population, the Covered Population counts 
published annually by the provincial Health Department was used.  These counts 
represent the population of Saskatchewan as of June 30 for each year.  For two- and five-
year age-specific rates, the population counts were averaged over those years within age 
groups for denominators.  
The merged analysis file was sent to the province’s Department of Health and 
linked to the Personal Registry System to obtain some patient demographic information, 
most notably, date of birth and place of residence.  The Health Department added the 
demographic information and assigned a unique identification number to each record 
before returning the files for analysis.  The working file had the patient names and Health 
Services Numbers removed in order to conform to University Ethics Board and 
Saskatchewan Health Data Access Review Committee approvals.  
5.3 Results 
To determine the completeness of our data, the reported numbers of PSA tests 
done by the labs were compared to the data retrieved electronically in our files (Table 
5.1a and Table 5.1b).  Table 5.1a shows the reported numbers of PSA tests analyzed by 
both the PH and RUH labs from 1997 to 2001.  The RUH did not have a reported number 
for 1998, so the number was estimated to be 9,100 based on extrapolation of the numbers 
from 1997 to 1999.  Given that estimate, there were 314,511 PSA tests done in 
Saskatchewan during 1997 to 2001. 
The PH lab counted fPSAs (to determine the free-PSA ratio) as a separate PSA 
test in their counts since it required a separate analysis with more reagent, even though it 
was on the same blood sample.  Table 5.1b, shows the number of records in our files by 
lab and whether a fPSA was done at the PH lab or not.  The data files contained 249,676 
records representing 79% of all PSA tests in the province for that time period.  Of those, 
13,113 PSA tests had an additional fPSA result determined.  Those events were 
reconciled into a single record for cases that had both total PSA results and an additional  
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Table 5.1a  PSA Test Volumes Reported by Labs  
    
 Year PH lab RUH lab Total   
 1997 45,798 3,298 49,096   
 1998 44,860 9,100* 53,960   
 1999 47,367 15,068 62,435   
 2000 51,370 18,208 69,578   
 2001 58,101 21,341 79,442   
 Totals 247,496 57,915 314,511   
 
 
* estimate based on linear extrapolation between 1997 and 1999 for PH 
lab, number includes total PSA plus a test for fPSA  
   
       
   
Table 5.1b  PSA Tests Provided in Electronic Files   
       
 Year PH lab Total PSA PH lab fPSA Total PH lab RUH Total 
 1997 27,106 0 27,106 0 27,106 
 1998 43,731 0 43,731 0 43,731 
 1999 46,121 983 47,104 0 47,104 
 2000 45,836 6,080 51,916 7 51,923 
 2001 52,705 6,050 58,755 21,057 79,812 
 Totals 215,499 13,113 228,612 21,064 249,676 
       
 Note: the fPSA record coincides with a total PSA from the Pasqua  
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fPSA result.  This resulted in 236,563 PSA records based on total PSA test results in 
Saskatchewan for the 1997 to 2001 period. 
The data for 2000 to 2001 were more complete than the data from 1997 to 2001 
because the dataset only included records from the RUH for 2001, but was missing for 
1997-2000.  To estimate PSA prevalence, men having at least one PSA test for the five 
years 1997-2001 and for the two-year period 2000-2001 were determined.  For the 2000-
2001 there were 119,598 PSA tests results available out of a possible 137,806 tests 
reported, excluding the fPSA tests.  Therefore the data represented 86.8% of the PSA 
testing in the province for 2000-2001.  The missing data would certainly not be evenly 
distributed over the province, but would presumably have mostly been from Saskatoon 
and surrounding areas.  
The 236,563 total PSA test results included men with and without known prostate 
cancer.  These tests were done in 107,037 different men for an average of 2.2 tests per 
man over the five-year period.  The primary interest of this study was the testing in men 
without prostate cancer at the time of their test.  There were 33,321 tests (14.1%) in men 
with a previous prostate cancer diagnosis.  Excluding them from analysis resulted in 
203,242 PSA test results where total PSA values were determined.  These tests were done 
in 102,681 individual men.   
The age distribution of the PSA tests in Saskatchewan for 1997 to 2001 for men 
with and without a previous prostate cancer diagnosis is shown in Figure 5.1.  A 
substantial portion (25.1%) of all PSA testing was in men under 50 or over 80 years of 
age.  Among men with no previous prostate cancer, 14.9% of tests were in men under 50 
and 9.8% of tests were in men over 80.  The median age of men tested who had no 
previous prostate cancer was 64 years.  For all men tested, the median age was 66 years. 
For the years 1997 to 2001, 52.1% of the men who did not have known prostate 
cancer at the time of their PSA test had just one PSA test in the time period (Table 5.2).  
Many men had more than one test and this proportion increased with age. Most of the 
men (84%) under 40 who were tested had only one test in the time period.  Of the tests 
done in men 40-49, 40.5% were in men who had more than one test.  This increased to 
46.2% for the tests done in men 50-59.  Of the men in both the 60-69 and 70-79 age 
groups 59.5% had more than one PSA test in the five-year period. Of note was that a  
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Table 5.2 Distribution of Men with no Previous Prostate Cancer who had PSA Tests by 
Age Group and Number of Tests, 1997 - 2001 
        
Frequency of Testing During 
1997 - 2001 Age Group* 
 
Number of PSA Tests
Total 
Men 
 
< 40 
 
40-49 
 
50-59 
 
60-69 
 
70-79 
 
80+ 
1 53,507 4,011 12,998 14,374 10,132 7,746 4,246
2 23,968 588 3,729 6,608 6,347 4,619 2,077
3 12,205 114 1,335 3,097 3,776 2,833 1,050
4 6,708 42 422 1,533 2,350 1,822 539 
5 or more 6,293 16 216 1,087 2,415 2,048 511 
Total Men with at 
least one PSA Test 102,681 4,771 18,700 26,699 25,020 19,068 8,423
        
* age was age at time of first PSA test during 1997 - 2001    
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significant number of men (8,423) over age 80 and under 40 (4,771) had at least one PSA 
test in the five-year period. 
As would be expected, the number of PSA tests ordered by urologists increased 
with age of the men tested (Table 5.3).  In the younger age groups, less than five percent 
of tests were ordered by urologists and most were ordered by general practitioners.  
Overall 82% of all tests were ordered by general practitioners.  Table 5.4 shows the PSA 
tests ordered for men who did not have prostate cancer at the time of their test.  Results 
show that the older the men, the higher the proportion of PSA tests ordered by urologists. 
But these proportions dropped markedly when the men diagnosed with prostate cancer 
were removed from consideration. Overall, most tests (87.3%) were ordered by general 
practitioners.  
The distribution of PSA test results by age group for men who did not have 
known prostate cancer at the time of their test is provided in Table 5.5.  Using a cutoff of 
4.0ng/ml to define as a ‘normal’ test result, we see an increasing percentage of men with 
abnormal total PSA with increasing age.  In the younger age groups less that 50, a very 
small percentage of men have total PSA above 4.0ng/ml.  For men in their 50s at the time 
of test, 6.7% had an abnormal total PSA.  This increased substantially to 18.9% for men 
in their 60s, 29.1% for men in their 70s and 36.9% for men over 80.  Using age-specific 
reference ranges to define tests as ‘abnormal,’ for men in their 50s, 60s and 70s the 
abnormal PSA test results would have been 8%, 16% and 18%, respectively.  Using age-
specific reference to define abnormal tests would have result in a 38% reduction in the 
proportion of abnormal tests (29.1% vs 18%) in the 70-79 age group compared to using 
the overall 4.0ng/ml to define the cut-off for abnormal test results.  
Figures 5.2a and 5.2b show the age-specific distribution of PSA test results in 
men who did not have a cancer diagnosed and in those who had a subsequent diagnosis 
(within 6 months of the last PSA test).  The vertical line in Figure 5.2a reveals both the 
total PSA level and the cumulative percent of men with no prostate cancer diagnosis at 
the point where 10% of the prostate cancers had been diagnosed for each age group.  In 
40-49 year olds, 10% of cancers were diagnosed in men with a total PSA of 1.3ng/ml or 
less (90% of cancers were higher than 1.3ng/ml).  Eighty-eight percent of men 40-49 with 
no prostate cancer diagnosis had a total PSA result under 1.3ng/ml. Older age groups  
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Table 5.3 Distribution of PSA Tests by Age of Man Tested and Physician Type (all 
PSA tests) 
      
Number of PSA Tests 
Age Group Urologist Oncologist Unknown 
General 
Practitioner 
Total 
PSA 
Tests 
 no.,  row % No.,  row % no.,  row % no.,  row %  
<40     96,    1.8 2,  0.0 406,  7.6 4860,  90.6 5,364 
40-49    683,    2.7 51,  0.2 1524,  6.1 22712,  91.0 24,970 
50-59  2665,    5.5 277,  0.6 2558,  5.3 42594,  88.6 48,094 
60-69   6773,  10.6 1076,  1.7 3336,  5.2 52439,  82.4 63,624 
70-79 10248,  15.7 1680,  2.6 3419,  5.2 50010,  76.5 65,357 
80+   4971,  17.1 375,  1.3 1717,  5.9 22091,  75.8 29,154 
Total 25436,  10.8 3461,  1.5 12960,  5.5 194706,  82.3 236,563 
 
 
Table 5.4 Distribution of PSA Tests by Age of Man Tested and Physician Type 
(excluding men with known cancer at time of PSA test) 
      
Number of PSA Tests 
Age Group Urologist Oncologist Unknown 
General 
Practitioner 
Total 
PSA 
Tests 
 no.,  row % no.,  row % no.,  row % no.,  row %  
<40      95,   1.8     2,  0.0   406,  7.6   4858,  90.6 5,361 
40-49     655,   2.6  18,  0.1  1519,  6.1  22657,  91.2 24,849 
50-59   2297,   4.9  58,  0.1  2518,  5.4  42037,  89.6 46,910 
60-69   4497,   7.9  81,  0.1  2991,  5.3  49263,  86.7 56,832 
70-79   4918, 10.0 110,  0.2  2674,  5.4  41584,  84.4 49,286 
80+   1735,   8.7  34,  0.2  1288,  6.4  16947,  84.7 20,004 
Total 14197,   7.0 303,  0.1 11396,  5.6 177346,  87.3 203,242 
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were associated with a higher PSA level where 10% of cancers had occurred. For men in 
their 50s, 60s, and 70s the PSA level was 3.2, 3.7 and 4.1 ng/ml.  These PSA levels in the 
older age groups (60s and 70s) accounted for fewer men without a PCa diagnosis, 83% of 
men in their 60s and only 75.6% of men in their 70s. 
The total PSA level and the cumulative percent of men with a PCa diagnosis are 
shown by the vertical lines in Figure 5.2b, at the points where 90% of the men tested did 
not have a prostate cancer diagnosis for each age group.  For men in their 40s, 90% of 
men had a total PSA less than 1.5ng/ml and at that level, 11.5% of the prostate cancers 
had been diagnosed.  For men in their 50s, 90% of men without PCa had a total PSA 
level of 2.7ng/ml or less while only 8.5% of the cancers had been diagnosed.  However, 
for older men in their 60s and 70s, the values were considerably different.  Ninety percent 
of men in their 60s who did not have PCa diagnosed had a PSA level of 5.2ng/ml or less 
but 20% of men diagnosed in that age group had PSA levels under that amount. Among 
the 70-79 year age group, 90% of men who did not have PCa diagnosed had PSA levels 
under 7.3ng/ml, but of the men who had PCa diagnosed, 27% were under 7.3ng/ml. 
Figure 5.3 shows the estimated percentage of men who were tested with PSA for 
the five-year period 1997 to 2001 and the two-year period 2000 to 2001.  The proportion 
of men having at least one PSA test was rather high especially in the 50 and over age 
groups.  At least 60% of men in their 50s, 70s and over 80 had at least one PSA test from 
1997 to 2001.  For men in their 60s, 58.5% had at least one PSA test.  Among men in 
their 40s, a significant 27% of men had at least one PSA test in the five-year period.  
When viewed over the two-year 2000-2001 time period, fewer men had at least one test.  
Even so, at least half the men in the province 60 or older had at least one PSA test over 
those two years.  Thirty-seven percent of men in their 50s also had at least one PSA test 
in 2000-2001. 
The age-specific proportions of men with at least one PSA test for each health 
region in Saskatchewan for 2000-2001 are provided in a map (Figure 5.4).  There was 
considerable variation in PSA use between the regions.  Among the 40-49 year age 
group, the range was 24.7% in Sun Country to 4.9% in the North.  Among 50 year olds, 
the range varied from a high of 45.1% in Sun Country to a low of 14.6% in the North.  
The region with the highest PSA tests use for 60 years old men was Sunrise at 58% and  
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Figure 5.4  Men With At Least One PSA Test by Age Group and Health 
Region, 2000-2001 
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the region with the lowest was the North at 21.2%.  The North had the lowest PSA use 
among 70-79 year old men while the highest rate was among men living in Sun Country 
at 64.9%.  Although the North had the lowest PSA test use for all age groups, there was 
still notable variation among the rest of the health regions with almost a 20% range 
between the highest and second lowest region.  In general, the south and east regions had 
the higher PSA rates and the north and west regions had the lower rates. 
5.4 Discussion 
The goal of this study was to investigate the use of the PSA test in the province of 
Saskatchewan where the test is available free of charge to all residents.  This study 
represented actual PSA data from lab records covering a five-year time period in the 
population of Saskatchewan.  For the entire period, the study was able to obtain 249,676 
PSA records covering 79% of the testing in population, making it the most 
comprehensive population-based study about PSA use to date.  When viewed as a two-
year period 2000-2001, this study represented almost 87% of all PSA testing done in 
Saskatchewan. 
Investigation of men with urinary or other urinary tract related symptoms warrants 
further investigation, perhaps using tests such as PSA.  This would be fairly common in 
older men but this does not explain the amount of observed testing in younger men, 
where prevalence of other non malignant conditions like BPH is very low.112  Given the 
number of PSA tests done and the size of our population, a substantial portion of the tests 
in men less than 50 years must have been done for screening purposes.  This is further 
supported by the fact that a majority of tests (over 90%) were ordered by general 
practitioners.  If most of the “unknown” physicians were also GPs, which is likely, then 
well over 95% of the PSA tests were ordered by general practitioners.  This finding was 
consistent with other work from the US, showing that the 35-49 year age group had the 
largest increase in testing between 1995-1999 and 2000-2001 based on survey data.113 
In Canada PSA screening is not recommended by the Canadian Task Force on 
Preventive Health Care, receiving only a “D” level of supportive evidence in favour of 
screening.114  The Canadian Cancer Society takes a more active stance, suggesting men 
over 50 discuss PSA screening with their doctor before deciding whether to proceed or 
not.115  In the United States, recommendations for PSA screening range from full support 
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to complete rejection.116  As well, advocates on the subject have been successful getting 
their messages out in the media.117   
Although clear benefits of PSA screening for prostate cancer has yet to be 
established, PSA testing was found to be very common in Saskatchewan men of all ages.  
Even the strongest proponents of PSA screening however do not usually endorse testing 
men over age 75 or in men less than 40.118  A substantial portion of the tests were found 
to be done in those age groups in Saskatchewan.  Over 27,000 PSA tests were ordered by 
general practitioners for men less than 50 years of age.  Regardless of the guideline 
considered, in Saskatchewan a considerable amount of PSA testing would have to be 
deemed inappropriate. 
Knowledge of PSA use is critical for understanding changes in incidence and 
mortality that occur over time and how testing potentially can impact health services.119  
After excluding men with known prostate cancer, an increasing proportion of men with 
higher PSA levels was found with increasing age group as expected.  In the absence of 
any contrary evidence, GPs in Saskatchewan are likely using 4.0ng/ml as the cutoff for 
defining test results as normal.  In the younger age groups, this resulted in few 
“abnormal” test results.  A big jump occurred from men in their 50s to men in their 60s, 
going from 6.7% of tests results over 4.0ng/ml to 18.9%, respectively.  Almost 30% of 
men in the 70s had PSA test results over 4.0ng/ml.  Urologists are more likely to use age-
specific ranges and if adopted by GPs, could make a substantial difference in follow-up 
and health services by reducing false positive results.  
The strength of this study was that PSA events and test results could be assigned 
to individual men.  Studies to date on PSA use have been survey-based or on selected 
samples which are then used to estimate population testing patterns.118, 120-123  This study 
shows that many men in Saskatchewan who did not have a previous prostate cancer 
diagnosis had more than one test during the study period.  As well, multiple testing 
occurred in all age groups but this was certainly more common in older men.   
Knowing who had a PSA test in the population also allowed for more accurate 
determination of testing coverage and to estimate screening rates.  Although PSA testing 
was found to be very common these results would certainly be slightly underestimated 
given some missing records for the time period from the RUH lab.  The missing records 
62 
are more likely to be from the Saskatoon region and are less likely to have been equally 
distributed throughout the province, so the underestimation probably has a greater effect 
on the Saskatoon regional rates.  Regardless, at least 60 percent of men 50-79 had at least 
one PSA test between 1997 and 2001 in Saskatchewan.  This result indicates slightly 
greater use of PSA testing than reported by men in the Canadian Health Surveys for PSA 
testing in Saskatchewan.  Surveys from 2000-2001 showed that 58.3% of men aged 45 to 
64 and 39.8% of men aged 65 to 74 reported never having had a PSA test. 124,125  Since 
PSA testing is freely available and indicated on standard requisition forms for blood 
work, it is certainly possible GPs order a PSA without sometimes patients being aware of 
it.   
There was significant variation in PSA use by health region in Saskatchewan.  As 
shown, most PSA tests are ordered by general practitioners and in Saskatchewan there are 
shortages of these physicians in some areas, most notably the far north and some of the 
rural regions.  Access to GPs could explain the lower prevalence of testing seen in the 
North and regions such as Prairie North and Heartland.  Saskatoon on the other hand is an 
urban centre and would not have as significant access issues.  Saskatoon more likely is 
underestimated as mentioned, due to some missing PSA records in the dataset from the 
RUH hospital.  The other potential factor for some of the higher testing rates could be the 
influence of large group practices in rural areas such as Sun Country.  If the philosophy 
of the group practice is to promote prevention and early detection, they will have a big 
effect on testing rates in those regions where that GP group might be the “only game in 
town”.  
In the neighbouring province of Alberta researchers found much lower PSA 
prevalence during a random digit dial telephone survey conducted in 1996.  Prevalence of 
PSA testing in men who ever had a PSA test was highest in 60-74 year old men but still 
only 22%.126  Alberta however was much more restrictive by not allowing PSA testing 
for screening purposes.  PSA testing in Saskatchewan was certainly higher due to the lack 
of any restrictions for PSA testing.  This is also consistent with other work that has shown 
insurance coverage increases likelihood of being tested.122 
The data in this study shows the actual experience of testing in an environment 
where PSA use is available at no cost to the patient.  Although screening is not endorsed, 
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it is clearly being widely practiced.  This research supports the recommendation that it 
would be appropriate to use age-specific reference ranges for normal values.127  As 
shown, choosing an age-specific PSA cutoff above which 90% of prostate cancer cases 
would be found provides fairly good specificity among men with no cancer, so not too 
many false positives are generated (1.3ng/ml, 3.2ng/ml, 3.7ng/ml, and 4.1ng/ml, in men 
40 to 49, 50 to 59, 60 to 69, and 70 to 79 years, respectively).  However, choosing a PSA 
cutoff level at the point representing 90% of men who did not have cancer (specificity) 
would result in potentially significant loss of sensitivity among men who have cancer, of 
as high as 20% and 27% in men 60-69 and 70-79, respectively.   
Oesterling et al recommended using cutoffs of 2.5ng/ml, 3.5ng/ml, 4.5ng/ml, and 
6.5ng/ml for men aged 40-49, 50 to 59, 60 to 69, and 70 to 79 years, respectively.127  
These values were determined from a study of men with no clinical evidence of prostate 
cancer and the cutoffs represented the 95th percentiles of PSA in these men.  It is difficult 
to know what the appropriate cutoff should be because it was not known whether men in 
this Saskatchewan study were diagnosed with the presence or absence of symptoms.  
Regardless, using Oesterling’s et al proposed cutoffs could potentially have resulted in 
missed cancer diagnosis, since 19.2%, 11.2%, 14.6% and 23.4% of the cancers were 
diagnosed in Saskatchewan men in those respective age groups and below those cutoff 
levels.  While age-specific reference ranges has merit, they might be required at lower 
cutoff levels as suggested by this study. 
The observation of PSA testing among the age group over 80 is more difficult to 
interpret.  A limitation of our provincial cancer registry is an underestimation of prostate 
cancer in the older population.  Cases with pathology are reported, however clinical 
diagnoses are the responsibility of the physician to report.  The registry does not have 
large numbers of clinically diagnosed cases but communications with urologists in the 
province indicates they have many clinically diagnosed cases in their practices, most of 
which are men over 80 with comorbidities.  This would also explain the much higher 
percentage of PSA ordered by urologists, who are using PSA as a follow-up in these 
patients.  For these reasons, the 80 and over age group was not included in some analyses 
identified as “men with no previous prostate cancer”, because in the oldest age group, 
that would certainly be inaccurate. 
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The study has some limitations.  The most significant was lack of information 
about the reason for the PSA test.  Certainly some men would be tested to investigate 
men with symptoms of prostate disease.  Benign prostate disease is common, especially 
in older men, so a portion of the tests would be in this group.  As well, some men could 
be without symptoms but have a family history of prostate cancer and screened as a high 
risk group.  Finally, some men would have been in a low risk screened group.  This 
information was missing making estimates of actual “screening” impossible.  What the 
results reflect is the prevalence of PSA testing in the population, for all reasons 
combined.  
The missing records were also a limitation.  Although the study included almost 
80% of all the PSA tests for the five-year period, the true prevalence is clearly 
underestimated.  If the missing PSA tests are distributed similarly by age etc and for the 
same reasons as in the study data set (screening, investigation of symptoms etc), the real 
population prevalence rates could be as high 75%, since 80% of the total tests produced a 
population testing prevalence of 60%.  It is not known where the missing tests would 
have come from in the population but most likely the Saskatoon region, which did show 
lower prevalence compared to the other large urban area of Regina.  Compared to the 
Regina Qu’Appelle Health Region, the prevalence of PSA testing for 2000 to 2001 was 
indeed about 20% lower in each group for the Saskatoon Health Region.  
The data presented represents a five-year window of observation of potentially 18 
years of PSA testing.  The test began to be used in 1990, so by 1997, it is highly likely 
that most men would have already had a test.  The men represented in the data who 
appeared only once, certainly could have been tested prior to 1997, so it is not known 
whether they were experiencing their first PSA test or a subsequent one.  
The information from this study is important to our understanding of the optimal 
ways to use this test in decision making.123  It is clear that in Saskatchewan, the lack of 
evidence of screening benefit has been overtaken by lack of evidence of harm.  With PSA 
testing being entrenched since 1990, it is conceivable that testing will continue even if the 
ongoing screening trials show no mortality benefit.  The public is well aware of the test, it 
is simple to take a serum sample, and the notion that finding cancer early has to be a good 
thing in all cases will be hard to counteract.  Issues of over-diagnosis of cancer are 
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generally not well understood by the public; for prostate cancer over-diagnosis leading to 
over-treatment is a very significant medical concern and is very costly to our publically 
funded health care system.128   
In the absence of definitive evidence of screening benefit, prevalence of PSA 
testing in Saskatchewan is high.  Since it is now unlikely the test would become an 
uninsured procedure after 18 years, it is more important than ever to monitor the use of 
this test and provide feedback to physicians about its potential for both harm and benefit.  
As well, with actual data in hand, it may be possible to alter what appears to be 
significant inappropriate testing in younger and older men.  Given that the data are 
available electronically in Saskatchewan and the data linkage capabilities, it would be 
prudent to form an ongoing single provincial database of PSA records.  Such a database 
would enable timely monitoring of PSA use, and provide excellent research opportunities 
investigating changes in prevalence of testing over time, individual PSA test results, and 
tracking practice patterns. 
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6.0 PROJECT 2.  DETERMINING THE IMPACT OF A NOVEL SCREENING 
APPROACH ON PROSTATE CANCER IN SASKATCHEWAN: THE FREE-PSA 
RATIO. 
6.1 Introduction 
Prostate specific antigen (PSA) testing for the detection of prostate cancer, while 
still controversial, is today well established in clinical practice.  Many studies have been 
conducted investigating additional clinical features combined with PSA testing to 
improve the sensitivity and specificity of the test.  These studies have included such 
additional measures as determining the prostate volume as it relates to total PSA 
(density),129,130,131 changes in total PSA levels over time,132-138 and determining the free-
PSA ratio.  
Prostate-specific antigen exists in multiple forms in serum and is predominantly 
bound to protease inhibitors; however, one form of PSA, free-PSA, is not bound to these 
proteins.139  Studies suggest that the ratio of free-PSA to total PSA, or the free-PSA ratio 
(fPSAr), can better discriminate between prostate cancer and benign prostatic disease 
than the total PSA alone.130,140-149  For unknown reasons, the fPSAr is lower in serum 
samples from patients with prostate cancer than in serum samples from patients with a 
normal prostate or benign disease.  Some evidence also suggests that a lower fPSAr may 
be associated with a more aggressive form of prostate cancer139 but others have shown no 
association with disease stage.150-152  
PSA testing became available to men in Saskatchewan in 1990.  PSA tests are 
funded by the Saskatchewan Health department and are free of cost to all residents in the 
province.  In August of 1999, the Pasqua Hospital laboratory in Regina, responsible for 
over 90% of PSA tests in the province at that time, introduced an algorithm for reflex 
testing for men with total PSA levels in the 4.0-10.0 ng/ml range (Appendix 1).  Reflex 
testing involves a reanalysis of the same serum sample to determine the fPSAr.  The 
advantage of reflex testing is that the same samples which produced PSA levels in the 4.0 
to 10,0ng/ml range are reanalyzed, requiring no additional samples from the patient.  The 
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results from the additional fPSAr testing were reported to all service providers who 
ordered a PSA test after November 1999. 
In a literature review and meta-analysis by Roddam et al investigating the 
diagnostic ability of the fPSAr in men with total PSA in the 4.0 to 10.0ng/ml range, they 
found that using the fPSAr could reduce the number of unnecessary biopsies while 
maintaining high cancer detection rate.153  Few details were available on the methodology 
of the studies involved and there were not many studies available in the reflex range of 
interest.  As Roddam et al suggested, more research is required about the use of the 
fPSAr to verify its optimal use.  
The purpose of this study was to determine the impact of the reflex testing and the 
provision of fPSAr test results had on biopsy and cancer detection rates in Saskatchewan.  
The hypothesis is that the additional information provided with a guideline for additional 
follow-up would make for more appropriate decision making in terms of who should 
have a biopsy.  Biopsy rates could have no change with an increase in cancer detection or 
biopsy rates could go down with no change or an increase in cancer detection in 
Saskatchewan.  
6.2 Methods 
Only two labs in Saskatchewan currently analyze serum for PSA, the Pasqua 
Hospital in Regina and the Royal University Hospital (RUH) in Saskatoon.  As 
mentioned PSA testing is fully covered by the provincial health plan.  Historically, the 
RUH only did PSA tests for in-hospital patients or as ambulatory cases prior to 1998.  
These tests were largely done as follow-up for patients at the cancer clinic located at the 
RUH.  In 1998, the RUH began to do analysis of PSA tests from community providers 
who largely would be general practitioners using the test for screening purposes.  Of all 
the PSA tests analyzed at the RUH, 50,000 are estimated to have been ordered by 
community-based practitioners between 1998 and 2001.  At the Pasqua Hospital lab, 
about 248,000 PSA tests were analyzed and it’s estimated that about 233,000 would have 
been of community-based origin for 1997-2001.  
Electronic records were only available beginning in May 1997 for Regina and in 
January 2000 for Saskatoon.  Based on the unavailability of Saskatoon records and the 
time frame of study, only Regina-based PSA tests were considered for study.  It has been 
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estimated that Regina-based PSA tests represent about 82% of all the community-based 
PSA tests done in the Saskatchewan population for the period May 1997 to December 
2001. 
Electronic records were obtained from the Pasqua Hospital for the period May 
1997 to December 2001.  Given that the reflex testing began in November 1999, this 
provided data for two-and-a-half years before reflex testing and two years two months 
after reflex testing.  In total, 232,923 PSA records were obtained from the Pasqua 
Hospital lab.  It should be noted that during the reflex testing period, when a total PSA 
was in the 4.0-10.0ng/ml range another record was generated for the free-PSA 
determination.  These records had to be reconciled into one event for each patient.  As 
well, duplicate records that were present were resolved.   
Information obtained from the lab included the date of the PSA test, the total PSA 
result, the free-PSA amount (for PSA tests that had a total PSA of 4.0 – 10.0 ng/ml), the 
name of the referring physician who ordered the test, and the patient Health Services 
Number (HSN).  The HSN is a unique number assigned to all residents of the province 
and is used when people interact with the health care system. 
The PSA records were linked to the population-based cancer registry housed 
within the Saskatchewan Cancer Agency.  The linking was done by using the Health 
Services Number.  Prostate cancer records were identified in the registry as all cases are 
coded using the International Classification of Disease for Oncology coding scheme.  
Data about tumour characteristics such as stage and Gleason scores were retrieved as well 
as the date of diagnosis and date of birth.  In this study date of diagnosis categorized men 
into two groups.  First, the date of diagnosis on which newly diagnosed cases were made 
after a PSA test, and second, identified men who already had pre-existing prostate cancer 
at the commencement of the study and were therefore having PSA tests as part of follow-
up care. 
The linked PSA and cancer data file was then sent to Saskatchewan Health for 
further linkages.  Saskatchewan Health maintains billing records for procedures done in 
the province, since health care coverage is the responsibility of the provincial 
government.  Procedures such as biopsies, transurethral resections of the prostate, and 
physician consult visits are billed for by physicians in the province.  Procedures are also 
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specific to physician specialties, for example general practitioners and urologists would 
have separate billing codes for consult visits.  Procedures were obtained if they were 
within two years after the date of the PSA test and before the date of a subsequent PSA 
test. The end date for procedures was December 31, 2003.   
Saskatchewan Health also maintains a list of all physicians in the province who 
are licensed to practice and bill for services.  The physician name from the PSA file was 
linked to the physician file at Health to determine the specialty of the physician who 
ordered the PSA test, specifically whether he or she was a general practitioner or 
urologist. 
Not all procedures in the province are necessarily billed for by all physicians.  
Biopsies during the period 1997 to 2001 were mostly done by urologists, who would bill 
for this service.  However in year 2000, prostate biopsies began to be referred to 
radiologists in the two largest centers, Regina and Saskatoon.  These procedures would 
not have been billed for by the radiologists because their service was paid for by the 
global hospital budgets and was not based on fee-for-service.  To make sure the dataset 
was not missing biopsy procedures, additional data was collected from the electronic 
systems of the pathology departments in Regina and Saskatoon.  These systems identify 
the tissue sample and the source procedure.   
The analysis was limited to men under 80 years of age at the time of their PSA 
test.  There were a significant number of tests in men over 80 years of age and many of 
these men had over 10 PSA tests each in the five-year study period.  This group of men 
presents an extremely difficult group to have their results interpreted because most would 
have been clinically diagnosed with prostate cancer and yet a significant number of those 
cases not registered in the provincial cancer registry.  Therefore cancer detection rates, 
primarily based on pathologic confirmation from cases in the registry, would severely be 
underestimated for this age group. 
Biopsy (and cancer) rates were determined by dividing the number of biopsies 
(and cancers detected) in men by the number of men who had a PSA test within ten-year 
age groups.  Although a man could potentially be in two age groups over the time period, 
they were assigned to one age group based on their age at the time of their first PSA test 
occurrence.  Rate ratios were calculated by dividing the biopsy (and cancer) rates during 
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the reflex testing time period by the rates determined prior to reflex testing.  Confidence 
intervals were calculated for rate ratios using a logarithmic transformation.154  
6.3 Results 
The numbers of PSA tests before and during the reflex testing period are shown in 
Table 6.1.  The numbers of tests in the two time periods are very similar, in fact, once the 
tests done in men with prostate cancer were eliminated, the number of remaining tests 
was the same, 92,699.  Table 6.1 show that the age distribution of the patients was the 
same in the two periods of study and that the distribution of total PSA test results was 
also very similar.  In each time period of study, men had more than one test on average 
and the average number of tests per patient increased as the total PSA test values 
increased.  In fact, there were many men in the population who had many more than one 
test over the five-year period, some having more than 10 (data not shown). 
The focus of the study was men who had total PSA results in the 4.0 - 10.0ng/ml 
range. Table 6.2 shows the age distribution and number of men who had an index PSA 
test in the 4.0 - 10.0 ng/ml range prior to reflex testing and during the first two years of 
reflex testing.  The age distribution of men again did not change between the two periods, 
and the number of men tested between two periods was also similar.  This age 
distribution for those men who had a total PSA in the 4.0-10.0ng/ml range was older than 
the distribution shown in Table 6.1 for men with any PSA test result.  Results shown in 
Table 6.1 therefore predominantly reflect PSA tests that were under 4.0ng/ml which 
would include younger men, since total PSA is age related. 
Table 6.3 shows the biopsy and prostate cancer detection rates by age group for 
men who had a total PSA in the 4.0 - 10.0ng/ml range, with and without the fPSAr 
determined.  For the men 50-59 at time of their PSA test, the biopsy rate increased 20% 
during the reflex testing period and this result was very close to statistical significance 
(95% confidence interval 0.98 to 1.48).  However the cancer detection rate in this age 
group increased 53% from 57.3 to 87.7 cancers per 1000 men which was statistically 
significant.  In men 60-69, the biopsy rate was unchanged but the cancer detection 
increased 12% with the fPSAr determination, albeit a non-statistically significant result. 
In the older age group, 70-79, the biopsy rate actually was reduced 17% which was 
statistically significant (95% confidence interval 0.73 to 0.95) but this did not affect the  
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Table 6.1 Age and Test Result Distributions for All PSA Tests in Saskatchewan 
Before and During the Reflex Testing Process 
 
 
 
Indicator 
 
Before Reflex Testing  
May 1997-Oct 1999 
Pasqua Hospital 
 
During Reflex Testing 
Nov 1999-Dec 2001 
Pasqua Hospital 
Number of PSA tests 108,794 106,705 
Tests done in men 
without known prostate 
cancer 
92,699 92,699 
Age of men tested   
25 percentile 55 54 
Median 65 64 
75 percentile 73 73 
PSA results (no. tests/no. men) (no. tests/no. men) 
<4.0 ng/ml 74,507 / 53,144 77,274 / 55,015 
4.0-10.0 ng/ml 12,976 / 7,822 11,370 / 6,869 
>10.0 ng/ml 5,216 / 3,178 4,055 / 2,427 
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Table 6.2 PSA Result was in the 4.0-10.0 ng/ml Range for Men 
Without Prostate Cancer at Time of Index PSA Test  
 
 
Indicator 
Before Reflex 
Testing  
May 1997-Oct 1999  
During Reflex 
Testing  
Nov 1999-Dec 2001  
Number of PSA tests 12,976 11,370 
Number of men 7,822 6,869 
Age of men tested   
25 percentile 65 65 
Median 71 71 
75 percentile 77 77 
Age group Number of men (% of total) 
Number of men 
(% of Total) 
50-59 768 (9.8%) 730 (10.6%) 
60-69 2619 (33.55) 2131 (31.0%) 
70-79 3117 (39.8%) 2796 (40.7%) 
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Table 6.3 Biopsy and Prostate Cancer Detection Rates for Men with Total PSA in 
the 4.0-10.0ng/ml Range 
 
Indicator 
Before Reflex Testing
May 1997-Oct 1999 
 
During Reflex 
Testing 
Nov 1999-Dec 2001  
Biopsies by 
age group 
 
number 
rate per 
1000 men 
 
number 
rate per 
1000 men 
Rate Ratio 
(95% CI) 
50-59 138 180.0 158 216.4 1.20 (0.98 – 1.48) 
60-69 503 192.1 413 193.8 1.01 (0.89 – 1.13) 
70-79 458 146.9 342 122.3 0.83 (0.73 – 0.95) 
Cancers 
detected by 
age group 
 
 
number 
 
rate per 
1000 men 
 
 
number 
 
rate per 
1000 men 
 
50-59 44 57.3 64 87.7 1.53 (1.06 – 2.21) 
60-69 196 74.8 179 84.0 1.12 (0.92 – 1.36) 
70-79 201 64.5 174 62.2 0.96 (0.79 – 1.17) 
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cancer detection, as the rate ratio was 0.96.  Historically, before any PSA testing was 
available in Saskatchewan, a majority of prostate cancers were detected from TURPs 
done to relieve symptoms of an enlarged prostate.  There was no significant change in 
practice or cancers detected by TURPS before reflex testing and during the first two years 
after reflex testing began (Table 6.4), which would account for the age-specific cancer 
detection changes noted in Table 6.3.  
Table 6.5 shows the distribution of the fPSAr by ten-year age group.  The 
categories used for the ratios were less than 0.10, 0.10 to 0.24, and greater than 0.24, 
which reflect the guidelines used by the Pasqua lab with physicians.  Of note, the highest 
percentage of fPSAr test results less than 0.10 (most indicative of cancer) was in the 
youngest age group 50-59.  In all age groups most fPSAr were over 0.24.  The percentage 
of cases in the 0.10 to 0.24 range increased with age from 14.7% of cases in the 50-59 
age group, to over 33% of cases in the 70-79 age group. 
6.4 Discussion 
This research was conducted to investigate the impact on the biopsy and prostate 
cancer detection rates in an era of determining the fPSA ratio for all serum samples where 
the total PSA was in the 4.0ng/ml to 10.0ng/ml range in Saskatchewan.  The introduction 
of the reflex testing procedure at the Pasqua Hospital lab to determine the fPSAr 
automatically for every total PSA test result in the 4.0-10.0ng/ml range had a significant 
impact on both biopsy and prostate cancer detection rates.  The difference was age-
specific, with the greatest impact on the younger men, specifically in the age group 50-59 
years at the time of testing. In this group, the biopsy rate increased 20% but the cancer 
detection rate showed an impressive relative 53% increase.  For younger patients, reflex 
testing had a clear beneficial effect by better discrimination of malignant from benign 
disease at biopsy and by overall better detection of prostate cancer. 
One reason for this was the 50-59 age group had the highest percentage of fPSAr 
under 0.10 resulting in more “appropriate” biopsies in this group than would have 
happened in the absence of the fPSAr.  The percentage of men with fPSAr less than 0.10 
decreased with increasing age, implying that the free unbound component of PSA is 
increasing more rapidly than the rate at which total PSA is increasing with age.  This  
75 
 
 
 
 
 
 
 
 
 
Table 6.4 Prostate Cancers Detected by TURPs for Men with Total 
PSA in the 4.0 - 10.0 ng/ml Range  
 
Age Group 
 
Diagnosed from 
1997 to 1999 
Diagnosed from  
2000 to 2001 
50-59 6.2% 7.6% 
60-69 15.0% 13.1% 
70-79 25.6% 22.9% 
  
 
 
Table 6.5 Distribution of fPSA Ratios (percentage of cases) by 
Age Group 
 
 
 
Age Group 
 
 
Ratio Less 
Than 10% 
 
Ratio Greater 
Than or Equal to 
10% and 
Less Than 24% 
 
Ratio Greater 
Than 24% 
50-59 17.8% 14.7% 67.6% 
60-69 12.3% 19.8% 67.9% 
70-79 8.8% 33.7% 57.5% 
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suggests that age-specific reference ranges for fPSAr are likely required to reflect similar 
age-specific reference ranges suggested for total PSA results. 
The impact however was not limited to the 50-59 age group.  While less dramatic, 
the biopsy rate for men in the 60-69 age group was unchanged, still a 12% increase in 
cancer detection was realized for men who are 60-69 years with reflex testing.  In the 70-
79 age group, cancer detection was unaffected but the biopsy rate decreased 17%.  The 
guidelines and information provided by knowing the fPSAr in all cases increased overall 
cancer detection 8.7% for all ages combined (50-79) while reducing the overall biopsy 
rate 4.7%. 
There are additional costs associated with using the reflex methodology.  Since 
every test in the total PSA range of 4.0ng/ml to 10.0ng/ml was automatically re-analyzed 
for fPSA, the men who had prostate cancer with this level of total PSA would have had a 
fPSA determined even though for them, it is not useful information.  Analysis of the 
records shows that in the 26 month period where fPSA was determined, just over 2200 
PSA tests had an fPSA done in men already known to have prostate cancer or about 1100 
unnecessary fPSA tests per year.  Currently there is no way for the lab to know if the 
serum being analyzed is in a man with or without prostate cancer and it could be that the 
marginal cost-benefit is such that current processes are adequate. 
In Saskatchewan, as in the rest of Canada, population-based prostate cancer 
screening is not endorsed by the Canadian Cancer Society.155  However, the evidence 
would indicate current practice is actually in favor of screening. Saskatchewan had a 
population of one million people in 1999, the middle year of the study period.  Of this, 
148,348 were men aged 50 plus and 119,937 were aged 50 to 79.156  In 1999 there were 
62,435 PSA tests analyzed in Saskatchewan. by 2001, over 80,000 PSA tests were 
performed.  Given these testing levels, population size, and the classic screening effect 
observed in age-adjusted rates after introduction of the PSA test in Saskatchewan as 
shown by Skarsgard and Tonita, significant prostate cancer screening is apparently being 
undertaken in Saskatchewan.3  Therefore, results of this study reflect the impact of 
determining the fPSAr for a population that is essentially experiencing extensive 
screening.  Unlike other published studies investigating the utility of fPSAr which are 
largely hospital or urology practice-based case control designs,139,157-160 this study reflects 
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the impact at the actual population-level of incorporating the fPSAr to all cases where the 
total PSA was in the 4.0 to 10.0ng/ml range.  
Some studies have also investigated whether the fPSAr can better predict extent 
of disease at time of diagnosis.150-152  These studies did not show there to be any benefit 
of knowing the fPSAr for staging of disease, they also did not have large numbers of 
cases to use for analysis.  Sakai et al had 147 prostate cancer patients and Aslan et al only 
42 to investigate stage and the fPSAr relationship.  This study had over 850 cancer cases 
diagnosed during the study period.  Analysis of the stage of disease showed no change in 
any of the age groups before or during the fPSAr era.  In all age groups, the vast majority 
of cases were organ-confined.  Although improving cancer detection, it does not appear 
that knowing the fPSAr has any additional benefit for determining the extent of disease.  
Gleason scores were also investigated in the cancer cases diagnosed.  What was 
interesting to note was a shift in the fPSAr period to more moderately differentiated cases 
from well differentiated cases.  In all age groups, the percent of cases moderately 
differentiated increased on average from about 63% to 84%.  This finding is difficult to 
interpret in relation to the fPSAr.  As a check, Gleason scores were also investigated for 
prostate cancers diagnosed during the same period but outside the 4.0- 10.0ng/ml range. 
While not as consistent in all age groups, a similar shift to more moderately differentiated 
cases was found in the other total PSA ranges (less than 4.0 and greater than 10.0ng/ml).  
The shift is less likely a result of the fPSAr and more likely the result of ongoing 
screening activity and the fact that more men in the fPSAr period would have been more 
likely to have had multiple tests.  Reasons for clinical investigation with multiple tests 
could have been due to changing total PSA levels, which may be more closely related to 
grade.  
Elabbady and Khedr161 investigated Gleason scores in 62 prostate cancer cases to 
see whether there was a relation between  fPSAr and higher and lower Gleason scores 
(Gleason scores 7-10 and 2-6, respectively).  They concluded that men with lower fPSAr 
had higher risk of elevated Gleason scores.  In 353 cancer cases diagnosed with fPSAr’s 
in this study, 27% had high Gleason scores and a fPSAr less than 0.15, 15.7% had high 
scores and fPSAr between 0.15 and 0.20, and  32% had high scores in the fPSAr range 
greater than 0.20.  The percentage of cases with the lowest fPSAr and the highest fPSAr 
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had very similar distributions related to higher and lower Gleason scores, suggesting no 
relation between the two factors.  
Incorporating the reflex methodology for the fPSA was like exposing the 
population to a natural experiment.  It happened at a point in time and throughout the 
population and no other changes occurred.  The primary limitation that could have 
influenced the results witnessed was repeat testing.  Men in the second time period 
(during reflex testing) could have had more previous PSA tests then men in the first time 
period prior to reflex testing, so the reason for biopsy may have been unrelated to the 
fPSA and more related to changes in total PSA over time.  It is certainly true that in the 
dataset, the two groups were not independent of each other.  Some men would have had 
PSA tests in both periods and could be represented therefore in each group.   
Again, the data did not have reasons for the PSA testing, so this impact is not 
simply in the screened group, but among all men tested for all reasons.  Since PSA testing 
had been in Saskatchewan since 1990, seven years before the study period began, it 
would seem reasonable that even men in the first part of the study period (without reflex 
testing) had considerable access to previous tests and were not likely much different than 
the men tested during reflex period.  
The data in this study covers a time period that begins in 1997 and concludes at 
the end of 2001.  However dated, it demonstrates the impact of determining the fPSAr at 
a population level, and with significant numbers, which is unique.  At present, the labs 
still operate using the same methods and the level of PSA testing in Saskatchewan 
remains high.  Updating the data with more years would allow for further analysis and 
would become a very valuable and unique source for research on population-based PSA 
testing.    
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7.0 PROJECT 3.  CHANGES IN CASE MIX AND TREATMENT PATTERNS IN 
PROSTATE CANCER IN SASKATCHEWAN DURING THE PROSTATE 
SPECIFIC ANTIGEN TESTING ERA 
7.1 Introduction 
The changes in incidence of prostate cancer have been significant since the 
prostate specific antigen test began being used for early detection purposes.  The debate 
about screening using the PSA test continues because of the lack of definitive proof from 
randomized trials that screening will reduce mortality from prostate cancer.162,163   
Consequently, numerous retrospective studies have been completed investigating the 
impact of PSA testing on incidence, case mix changes, and mortality in an attempt to 
understand the usefulness of this test.  
In earlier work we showed the impact PSA testing had on the incidence, mortality, 
and survival of prostate cancer in the province of Saskatchewan in Canada.3  
Saskatchewan is unusual in North America because all residents of the province have 
access to health care through the provincially funded health plan and the PSA test is 
insured under that plan, making it free of charge to all men.  The PSA test became 
available to men, in Saskatchewan in 1990.  The impact of PSA testing on incidence was 
immediate, as the age-adjusted rate increased 60% from 96.4 per 100,000 in 1989 to 
153.9 per 100,000 in 1993.  Then from 1994 to 1997 the incidence dropped, returning 
closer to the trend established before 1990.  This pattern is indicative of a screening effect 
resulting from the introduction of PSA testing.  During the PSA era, survival of 
diagnosed cases improved but mortality rates remained steady indicating a lead time 
effect from the earlier diagnosis of cancer. 
These changes in incidence of prostate cancer with the introduction of PSA 
testing are consistent with alterations in the case-mix of the disease, with tendency for 
increased diagnosis of earlier staged cases.  Stage migration, meaning a tendency to 
detect disease when it is in earlier stages of development is an indicator of the 
effectiveness of a screening test, and consequently, it may predict an eventual reduction 
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in mortality as well.164  Diagnosing cases earlier has been reported in other jurisdictions 
where the PSA test is used, but most studies are not population based.165-168  We were 
unable to confirm a stage migration in our previous study because of a lack of reliable 
information on tumor characteristics in the provincial cancer registry.  Changes in case 
mix could also result in changes in treatment, but again the provincial cancer registry 
does not contain complete information in this area.   
The hypothesis is that PSA testing in Saskatchewan has shifted the stage 
distribution of prostate cancers detected to more organ confined cases and consequently 
that changes in clinical management of the disease has resulted.  The purpose of this 
study was to describe the changes that occurred in the case-mix and in treatment patterns 
for prostate cancer in Saskatchewan after the introduction of the PSA test in 1990. 
7.2 Methods 
A detailed description of the Saskatchewan Cancer Registry (SCR) is available 
elsewhere.3  In brief, cancer is a reportable disease in Saskatchewan.  Pathology reports 
are sent to the SCR if there is any mention of in situ or invasive cancer.  The anatomic 
site and morphology of each cancer is coded in the SCR using the International 
Classification of Diseases–Oncology (ICD-O) system.103  The SCR contains dates of 
diagnosis, patient demographic information, and dates of follow-up.  Information on date 
and cause of death comes to the SCR from the provincial Department of Vital Statistics 
on a regular basis. Death information is coded using ICD-10 classification.169  We 
included only the deaths where prostate cancer was the primary cause of death in 
calculations of mortality rates.  
Extent of disease and treatment information for prostate cancer was not available 
in the SCR.  We conducted a large chart review to provide information on tumor 
characteristics and treatment for all men diagnosed with prostate cancer in Saskatchewan 
from 1985 through 2001, a period spanning the introduction of PSA testing in 1990.  We 
identified, within the SCR, all cases of prostate cancer for these years.   
Our intent was to study prostatic adenocarcinomas, which represent about 97% of 
neoplasm’s involving the prostate gland.  We therefore limited our analysis to ICDO-M 
morphologic codes 8140 (adenocarcinoma), as well as 8000 (neoplasm not otherwise 
specified) and 8010 (carcinoma not otherwise specified), a group of cancers which will 
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subsequently be referred to as prostatic adenocarcinoma, or prostate cancer (PCa).  We 
included the latter two categories of poorly-defined cancers in the above group because, 
in the absence of any information suggesting otherwise, the overwhelming likelihood was 
that they were adenocarcinomas. 
The extraction generated 10,691 total prostate cancer cases for the time period 
1985 to 2001.  Of these, 10,361 (96.9%) had the morphologies of interest and we were 
able to review 10,018 (96.7%) of the eligible charts.  A modified American Urological 
Association staging system was used to establish extent of disease at the time of 
diagnosis.  Stage A was clinically occult, B was cancer limited to the prostate, C included 
local extension, and stage D was metastatic to lymph nodes, bones or other distant sites.  
Other information collected from the review included, Gleason score, PSA level at 
diagnosis, method of diagnosis, and information specific to the first course of treatment, 
and follow-up status at time of chart review. 
The charts were reviewed by trained health records technicians under the 
supervision of a radiation oncologist (DS), who also reviewed all charts during the 
training period.  To assist the technicians, a detailed set of rules for data collection was 
produced and regularly updated as new situations were encountered to ensure all cases 
were dealt with consistently.  The technicians were also able to send charts to the 
oncologist for review and clarification if they had questions.  As well, a random audit was 
done on approximately 20% of charts by the oncologist to establish error rates in the data.  
Errors were also corrected if found.  Based on the audit and corrections, the error rate for 
stage and Gleason score is estimated to be three percent or less in the entire dataset.  
The provincial health department maintains population files for residents who are 
eligible for health services.  These population files provided the denominators to calculate 
age-specific rates.  Age-adjusted rates were standardized to the 1991 Canadian 
population.   
7.3 Results 
Figure 7.1 is an update of earlier work with the addition of the years 1998-2001.  
The age-adjusted incidence of prostate cancer increased substantially again during the 
1997 to 2001 period, corresponding to another large increase in PSA testing in 
Saskatchewan.  by 2001, the age-adjusted incidence reached the peak levels witnessed in  
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1993.  The pattern was similar in Canada, although the peak level in 1993 was somewhat 
lower than in Saskatchewan and the data point for 2001 is an estimated value.170  In 
Saskatchewan, just about 80,000 PSA tests were done in 2001; almost double the number 
from 1993.  
For the entire time period 1985 to 2001, 27.0% of cases were Stage A or clinically 
occult, 36.9% were Stage B or limited to the prostate gland, 12.0% had local extension 
(Stage C), and 15.4% had metastases at diagnosis (Stage D).  Some cases (2.8%) were 
known not to be Stage D and 6.0% could not be staged at all.  Fifty-two percent were 
moderately differentiated (Gleason scores 5, 6, 7), 28% were well differentiated (Gleason 
scores 2, 3, 4), 14.5% were poorly differentiated (Gleason scores 8, 9, 10), and 4.7% had 
unknown grade.   
The age-adjusted rate of prostate cancer at Stage A did not change over the time 
period 1985 to 2001 (not shown).  Since the distinction between Stage A and B may not 
be meaningful during the time period that spans the introduction of PSA testing, which 
may have biased staging, Stage A and B were combined into a group termed “Organ 
Confined” (Figure 7.2).  The large increase in the overall incidence was mostly organ 
confined cases, where the rate increased from 38.5 per 100,000 in 1985 to 108.8 per 
100,000 in 2001.  Locally advanced disease was  highest in 1991 at 18.7 per 100,000 but 
decreased to 8.2 per 100,000 by 2001.  The incidence of metastasis has declined since 
1992 when the rate was highest at 19.4 per 100,000. by 2001, the rate of metastasis had 
dropped to 13.5 per 100,000.  
There has been a large increase in the age-adjusted incidence of moderately 
differentiated cases over time, as the incidence is over three times higher in 2001 than in 
1985 (Figure 7.3).  The incidence of well differentiated cases has dropped 50% since 
1993-1994, while the incidence of poorly differentiated cases has remained very stable 
over the entire 17 year period. 
Age-specific incidence rates are shown in Figure 7.4.  Incidence rates have 
doubled for men 55-59 (100 per 100,000 in 1985 to 200 per 100,000 in 2001) and 60-64 
(200 per 100,000 in 1985 to over 400 per 100,000 in 2001) years of age.  For men 65-69, 
the rate increased from 300 per 100,000 in 1985 to over 800 per 100,000 in 2001.  The 
pattern of increase in the 70-74 year age group was most similar to the overall age- 
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adjusted rate, with a peak incidence in 1993-1994, followed by decreases to 1998, and 
another increasing trend to 2001.  The pattern was also similar in the 75-79 age group but 
the change in incidence was not as great as the 70-74 age group.  Incidence in the 80+ age 
group peaked at almost 1,200 per 100,000 in 1992-1993 and has remained below that 
level ever since.  Since 1993, the incidence in the 70-74 and 75-79 year age groups has 
been consistently higher than the incidence in the 80+ age group. 
Figure 7.5 shows the incidence of organ confined disease by ten-year age groups.  
The incidence has increased by a factor of four for men 50 to 59 years of age, from 13 per 
100,000 in 1985 to 51 per 100,000 in 2001.  For men 60 to 69, the rate increased from 41 
to 135 per 100,000 and for men 70 to 79, the increase was from 84 to 187 per 100,000 for 
the same years.  The organ confined rate did not show any pattern of change for men 80 
and older over the 17 years.   
The pattern is quite different for the diagnosis of Stage D cases by age as shown 
in Figure 7.6.  For men 70 to 79 and 80+, the average incidence of metastasis from 1985-
1989 to 1997-2001 dropped 44% and 39%, respectively.  The diagnosis of metastasis in 
men 50 to 59 dropped from an average of 6.6 per 100,000 in 1985-1989 to 4.8 per 
100,000 for 1997-2001, a relative reduction of 27%.  For men in their 60’s, the average 
rate fell 21% from 15.8 to 12.5 per 100,000.  The diagnosis of locally advanced disease 
dropped significantly in all age groups, except for men aged 50-59, for whom the rate 
was stable (not shown). 
Age-specific mortality rates from prostate cancer are shown in Figure 7.7.  There 
has been little change in death rates among the 50-59 and 60-69 age groups for the years 
1985-2002.  When viewed as three six-year periods (1985-1990, 1991-1996, and 1997-
2002), the average death rate in the 50-59 year age group was 8.9, 9.9, and 9.1 per 
100,000, respectively. In the 60-69 age group, the average death rate for the three periods 
was 57.2, 66.7, and 56.4 per 100,000, respectively.  The pattern was different in the two 
older age groups.  Among those 70-79, the average death rate was 222.3, 228.5, and 
240.7 per 100,000, respectively, and in the 80 plus age group the average rates were 
623.3, 657.2, and 746.5 per 100,000, respectively.   
Among the men diagnosed with Stage A prostate cancer during 1985-1999 and 
who are known to have died (deaths by August 2002), 19% (211 of 1085) died of prostate  
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cancer.  Among men with Stage B at diagnosis, 37% (506 of 1367) died of disease, and 
for men with Stage C, 54.5% (421 of 773) died of prostate cancer.  Seventy-eight percent 
(936 of 1197) of men diagnosed with metastases (Stage D) died of prostate cancer. 
The total number of prostate cancer cases doubled over time from 400 to 800. The 
number of cases with metastasis at diagnosis dropped.  For the period 1985-1989, there 
was an average of 93 Stage D cases diagnosed per year.  For the period 1996-2001, the 
number of Stage D cases dropped 16% to 78 new cases per year.  However when viewed 
as a proportion of total new cases, Stage D dropped from 22.1% of all cases in 1985-
1989, to only 11.8% of all new cases diagnosed in 1996-2001, a decrease of 46.7%.   
The investigation and management of prostate cancer has changed during the PSA 
era as well.  Table 7.1 shows that prior to the PSA testing (1990) most prostate cancers 
were detected from transurethral resections of the prostate (TURP) and about one third 
were diagnosed from needle biopsy.  By 2000-2001 however, only about 20 percent of 
prostate cancers were detected from TURPs and three quarters of cases were diagnosed 
by needle biopsy.  During the same period, the treatment for prostate cancer also changed 
dramatically.  Prior to PSA testing, most cases were treated with radiation therapy, 
hormone therapy or watchful waiting.  Over time, surgery became more common and in 
2001 accounted for almost 20 percent of the first course of treatment.  Hormone therapy 
dropped as the first course of treatment from 35.8% of new cases in 1985 to 18% in 2001. 
Table 7.1 suggests that men are more likely to have radical treatment during the 
PSA era.  Table 7.2 shows the first course of treatment for men who were 70 or less at 
diagnosis and who had organ confined disease.  These men would have been eligible for 
all treatment options.  Prior to 1990, almost half of men chose radiation therapy and only 
14 percent had surgery.  For the time period 1997-2001, when PSA was firmly 
established, 81% of cases had radical therapy, with equal numbers of men choosing 
surgery as those choosing radiation.  The percent of men choosing conservative treatment 
dropped from 36.8% prior to PSA to 19% in 1997-2001. 
7.4 Discussion 
Saskatchewan is an interesting population to investigate the impact of PSA testing 
given the test is available free of charge to all residents, the population is very stable and 
fairly homogeneous in terms of race.  The population is primarily white with a growing  
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Table 7.1  Method of Diagnosis and First Course of Treatment for Prostate 
Cancer in Saskatchewan, 1985-2001. 
 
 
Method of Diagnosis 
(% of cases diagnosed that 
year) 
First Course of Treatment 
(% of cases diagnosed that year) 
Year 
Needle 
Biopsy TURP Other* RP RT Hormones None 
1985 34.1 60.4 5.5 2.4 27.9 35.8 33.9 
1986 39.5 54.2 6.3 1.5 30.1 35.7 32.7 
1987 35.3 57.0 7.6 2.1 29.6 37.7 30.5 
1988 35.0 60.1 4.9 5.4 23.4 33.9 37.4 
1989 35.3 59.1 5.6 6.0 31.5 31.7 30.7 
1990 39.8 54.6 5.5 6.7 27.6 34.5 31.2 
1991 51.1 44.3 4.6 8.2 33.6 35.7 22.5 
1992 57.5 37.7 4.8 11.1 31.5 31.2 26.2 
1993 67.7 27.3 5.0 8.9 30.7 33.0 27.3 
1994 74.5 20.9 4.6 10.7 32.6 31.1 25.6 
1995 73.8 24.8 1.3 10.1 32.9 30.2 26.8 
1996 75.1 24.0 0.9 11.4 34.6 27.9 26.1 
1997 77.7 21.0 1.3 11.7 32.2 28.7 27.3 
1998 74.2 22.3 3.5 12.5 30.9 25.1 31.6 
1999 76.0 22.5 1.4 14.6 32.1 21.7 31.6 
2000 73.8 21.8 4.4 17.9 31.0 23.1 28.0 
2001 76.1 19.7 4.3 19.7 32.1 18.0 30.2 
 
* Other diagnostic methods include clinical and radiological 
TURP is a transurethral resection of the prostate 
RP is a radical prostatectomy 
RT is radiation therapy 
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Table 7.2  First Course of Treatment Chosen by Men Who Were 70 Years of 
Age or Less When Diagnosed with Organ Confined Prostate Cancer, by 
Time Period 
 Choice of First Treatment (Percent of Men) 
Time Period of 
Diagnosis 
Radical 
Prostatectomy  
Radiation 
Therapy  
Conservative 
Treatment*  
1985-1989 14.4 48.8 36.8 
1990-1996 32.4 45.4 22.2 
1997-2001 39.5 41.5 19.0 
 
First course of treatment was treatment in the first six months after 
diagnosis 
 
* Includes hormone therapy or watchful waiting
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First Nations (aboriginal people also known as North American Indian) population.  The 
First Nations group represents about 13% of the total population but only about 5% of the 
population 45 years of age or older.171 
In Canada routine screening with PSA is not recommended.17  Incidence patterns 
and PSA volumes in Saskatchewan however, suggest a large amount of screening is 
taking place.  Our incidence increased dramatically when the PSA test was introduced 
and by 2001, 80,000 PSA tests were done in the population that had only 122,000 men 
aged 50 to 79.172  There was one downward blip in PSA use in 1995, when provincial 
guidelines were released in Saskatchewan recommending against routine screening for 
prostate cancer with PSA.16  After only one year, test use returned to previous trends, 
likely fueled by both patient demand and strong recommendations supportive of 
screening from organizations such as the American Cancer Society and the American 
Urological Association.  While some increasing test use would be for follow-up in men 
with known prostate cancer, a significant portion must have been for screening purposes 
given these volumes, this population size, and our current incidence levels.   
Screening using the PSA test has resulted in significant changes in the diagnosis 
and management of prostate cancer.  As well, tumor and patient characteristics have 
changed considerably.  In the United States, stage migration occurred to more organ 
confined tumors at diagnosis during the PSA era.173, 174  Patients are also younger at 
diagnosis during the PSA era which has resulted in a shift towards more definitive 
treatments such as radical prostatectomy and brachytherapy, while the proportion of cases 
treated with external beam radiation and hormone therapy remained fairly stable.175  In 
Canada, the age-adjusted rate of radical prostatectomy increased from under 20 per 
100,000 in 1990-91 to 71 per 100,000 by 1998-99.176  In Saskatchewan, we also saw a 
shift in the age of men diagnosed.  Prior to PSA testing, 30% of men were under 70 years 
of age at diagnosis and by 2001 this had increased to 42%.  Consequently, we have seen 
similar changes in the first course treatment, with 20% of men having definitive surgery 
in 2001 compared to less than 5% prior to PSA testing.  
We used a modified American Urological Association staging system for our 
chart review.  It would have been informative to break down the staging into sub 
95 
categories given the numbers of cases we had but this could not be done reliably in a 
rather large portion of cases in our population-based study. 
Whether mortality reductions will result from the earlier diagnosis of prostate 
cancer and from the shift to more radical (curative) treatment intent is unknown.  In a 
study looking at treatment patterns and mortality in Connecticut, Iowa, and New Mexico, 
radical prostatectomy was found to have increased by factors of 3-4 since the introduction 
of PSA testing, similar to what happened in Saskatchewan.177  In Connecticut and Iowa, 
mortality was shown to increase but it decreased in New Mexico.  In Saskatchewan we 
found death rates were stable for the younger age groups but increased in the 70-79 and 
80+ age groups for the years 1997-2002. 
An investigation of incidence and mortality trends in the United States and 
Canada showed that mortality from prostate cancer in Canada was declining in men over 
60 years of age after 1993.178  Prior to these declines, mortality had been increasing since 
1969.  Saskatchewan represents only about 3% of the population of Canada therefore the 
Canadian rates are minimally influenced by the Saskatchewan population.  The trends 
witnessed in Canada are likely partially due to attribution bias, a misclassification of 
cause of death brought on by changing incidence trends that influence physician’s 
decisions about reporting cause of death on death certificates.179,180  This bias was likely 
partially present given the prostate cancer mortality in Canada was increasing up to 1993 
then dropped afterwards, which was the same pattern that happened with Canadian 
incidence rates.  This bias could have been more prevalent in Saskatchewan, because 
PSA use was likely more common here than the rest of Canada as indicated by our 
overall higher incidence rates and free availability of PSA, which was not common in all 
provinces.  This could explain our slightly higher age-adjusted prostate cancer incidence 
rates for the years 1994-2002 and subsequently our higher mortality rates.4 
Prostate cancer tends to be slow growing and the prevalence of latent tumors 
(those with minimal risk of metastasis) is high in older men.181  Detection of these latent 
tumors through increased screening activity would result in unnecessary treatment of men 
who may not require medical intervention.174  But PSA testing has primarily resulted in 
an increase in the diagnosis of organ confined moderately differentiated tumors.  This 
finding is consistent in areas where widespread PSA use has taken place.173,175,180  These 
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tumors are considered medically important and are still curable using current 
techniques.173,182  The shift towards moderately differentiated tumors is consistent with 
diminishing low grade detection through the 1990s, as low grade tumors are now more 
commonly referred to as non invasive atypical adenomatous hyperplasia.183   
Screening would be expected to reduce the incidence of metastatic disease and 
eventually lead to reductions in mortality.164  In Saskatchewan, the reduction in 
metastasis was only in men in their 70s and over 80, but not in younger men.  As well, 
the increase in organ confined disease was in the younger men and not older, suggesting 
that PSA testing has shifted the detection of distant disease in older men to diagnosis of 
earlier organ confined disease in younger men.  This might result in a reduction of 
prostate cancer mortality in the older men but still could have very little influence on their 
overall survival because of competing risks in old age.184  What is more noteworthy 
perhaps, is that the incidence of metastatic disease has not changed in men under 70, the 
men who have more to gain in overall survival if prostate cancer deaths could be avoided. 
The study was population-based and provides a thorough understanding of the 
affect of PSA testing on tumour characteristics and treatment patterns.  It is clear from the 
data retrieved from the Cancer Registry however, that cases are missing in the 80 and 
over age group.  Given its strong relationship to age, it did not make sense that the age-
specific rates of men in their 70 would overtake the rates for men in their 80s.  
Consultations with urologists in the province indicate that these older men are more often 
clinically diagnosed and not reported to the Registry even though they should be by 
legislation.  This makes trends for the oldest group very difficult to interpret given the 
level of under reporting is unknown.  
Investigation of tumour and treatment patterns provides useful information about 
the impact of widespread PSA testing in the population.  The limitation is that it does not 
tell us whether PSA testing is beneficial or not for mortality.  In our population we have 
seen no change in mortality trends.  But it could be that not enough time has elapsed for a 
mortality benefit to materialize.  Had our mortality trends shown change, it would still be 
difficult to attribute any reduction solely to PSA screening given the changes that also 
occurred in treatment over the same years.  Benefit of PSA screening for prostate cancer 
will only be proven through randomized screening trials.   
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The European Randomized Screening for Prostate Cancer trial is not expected to 
have results until the end of 2008.185  The Prostate, Lung, Colorectal, and Ovary cancer 
trial will also not have results for a number of years yet.186  In Saskatchewan, where 
widespread use of the PSA test has been in place for 18 years, prostate cancer mortality 
has thus far not declined. 
 
98 
 
 
 
8.0 GENERAL DISCUSSION 
There were a number of key objectives associated with this research. One 
objective of this research was to determine the extent of PSA testing in Saskatchewan, 
and determine the impact of testing in the population which has had free access to the test 
since 1990.  Another objective was to explore changes in the case mix and clinical 
management of prostate cancers diagnosed during the time of PSA testing.  The findings 
were striking.  
Prostate cancer has been the most common diagnosed cancer in Saskatchewan for 
many years. During the PSA era there was a dramatic increase in the number of new 
cases.  In Saskatchewan before PSA testing there were some 500 new cases per year, but 
in the PSA era this number had grown as high as 900.  The increase has been seen in all 
age groups most notably those under 80 years of age.  In fact, cancer incidence is now 
higher in men 75-79 than it is in men over 80, a finding that contradicts what we know 
about prostate cancer risk continually increasing with age.  There are two likely 
explanations for this.  One, more PSA testing occurs in men under 80, so more men are 
investigated and found to have disease since the prevalent pool is large. Second, it is 
almost a certainty that many men over 80 are diagnosed with prostate cancer clinically 
and many of these are not reported to the provincial cancer registry although they are 
supposed to be by legislation.  Regardless, the health care system is treating a 
significantly higher number of new cases per year than it did prior to PSA testing.  
The increase in prostate cancer incidence largely consists of organ confined 
moderately differentiated cases and this is consistent with screening activity and what has 
been witnessed in other jurisdictions where PSA testing is common.  The diagnosis of 
metastatic disease is also showing signs of dropping in the population.  However, we 
have not seen any drop in prostate cancer mortality as yet in Saskatchewan.  Given that 
ongoing screening trials have not yet shown mortality benefit from screening for prostate 
cancer, it is difficult to know whether all the screening activity will result in reductions.  
It may be that enough time has not yet elapsed for the reduction to have occurred, or it 
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may be that screening will have no impact whatsoever on mortality.  The answer remains 
unknown. 
PSA testing has also significantly changed how prostate cancer is managed.  More 
cases are now diagnosed by needle biopsy (at least 75%) versus transurethral resections 
of the prostate, which was much more common prior to PSA testing.  In other words, 
where we used to find prostate cancer serendipitously (60% diagnosed by TURP prior to 
PSA testing), we now find it because we are looking for it.  As well, in Saskatchewan we 
are finding it more commonly in younger men, as the cancer incidence rates more than 
doubled in men 55-59, 60-64 and 65-69 years from 1990 to 2001.  This potentially could 
prove beneficial, as younger men have more to gain from early diagnosis than men in 
their 70s who have less life expectancy.  Treatment patterns have also changed with the 
diagnosis of younger men in recent times.  More men are being treated with radical 
surgery (40% of men under 70 years) and fewer men being treated by hormone therapy 
than prior to PSA testing.   
These changes have been largely driven by the use of the PSA test in 
Saskatchewan.  The test has been available for physicians for use at no cost to patients 
since 1990, a fairly unique situation in the context of practices seen in Canada and 
abroad.  This research shows PSA testing is very common in Saskatchewan with many 
more men having had at least one PSA test than suggested by previous surveys.  The 
study showed that men of all ages are having PSA tests, many younger than 50.  
Surprisingly, 27% of men in their 40s were found to have had at least one PSA test in the 
five-year period of study.  As well, over 5300 tests were ordered for men less than 40 
years, a result not remotely expected.  Even organizations that support PSA testing do not 
recommend screening in these age groups.  Many men over 80 are also tested in 
Saskatchewan (over 60%), although that could be for various reasons; follow-up of 
clinically diagnosed prostate cancer, investigation of symptoms etc.  Still, these are 
astounding levels of testing in the absence of proof that prostate cancer screening is 
beneficial.   
PSA test use was found to be all over the map, literally.  Geographically, testing 
rates varied in Saskatchewan, with men in northern regions being tested less frequently.  
Even excluding the far North, the range varied by 20 percentage points between health 
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regions in all age groups.  Limited access to general practitioners would certainly 
contribute to variation in these rates since they order about 90% of the PSA tests and in 
Saskatchewan, we know there are rural and remote areas with shortages of physicians.   
PSA testing frequencies among men with no previous prostate cancer diagnosis 
were also extremely variable, some men having one test in a five-year period, others 
having 20 or more.  Among the youngest men less than 40 years of age with no prostate 
cancer at the time of their PSA test, 16% of men tested had more than one PSA in the 
five-year period and in the 40 to 49 year age group, this was 30%.  The lack of clear 
guidelines or perhaps guidelines that are supported by clear evidence creates an 
environment prone to considerable variation among physicians and how they are using 
the PSA test.  There is without doubt, substantial inappropriate use of the PSA test in 
Saskatchewan. 
As expected, PSA test results in the population were very age-specific and would 
suggest that referrals to urologists could be better controlled if age-specific levels for 
further follow-up were used.  This research shows the cumulative distribution of total 
PSA in the population diagnosed with prostate cancer and those who were not.  Choosing 
which cutoff depends on ones perspective of the tradeoff between sensitivity (finding 
cancer when its there) and specificity (not referring men who do not have cancer).  If 
finding cancer is most important, total PSA will have to be lower in each age group but 
then many men would need to be referred who do not have cancer.   
Biopsy rates however, can likely be reduced and not at the expense of prostate 
cancer detection by using age-specific cutoffs for further investigation.  PSA levels 
increase with age so it makes sense to have “abnormal” levels that reflect that very strong 
relationship.  As well, the number of urologists in Saskatchewan is low, so anything that 
streamlines their time and has them investigating more relevant cases would be very 
beneficial and more efficient.   
We experienced an interesting natural experiment in Saskatchewan with the 
addition of the reflex testing procedure to determine the free-PSA ratio among all men 
with a total PSA in the 4.0 to 10.0ng/ml range.  This experiment was population-based 
and provided an excellent opportunity to analyze the impact of the additional information 
on men and their outcomes after testing.  The impact was found to be age-specific.  Men 
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in their 50s had a statistically significant 53% increase in cancer detection rate while the 
biopsy rate increased 20%.  For men in their 70s, there was a significant 17% reduction in 
biopsy rate with no change in cancer detection. Overall for men aged 50-79 the reflex 
process resulted in slightly fewer biopsies (reduction of 4.7%) but overall, better cancer 
detection (increase in detection rate of 8.7%), a very significant finding in support of 
reflex testing and the fPSA test. 
This research did not investigate the reasons for observed testing levels in 
Saskatchewan.  But there are some factors that certainly play a role.  One major driver of 
PSA use has to be that in Saskatchewan PSA testing is available free of charge to all men.  
If a man wants the test, he is most likely going to have it since physicians have little time 
to discuss all the potential benefits and harms; it is easier and quicker to just order the 
serum sample.  The conflicting guidelines and recommendations about prostate cancer 
screening means that physicians will be on both sides of the argument depending on their 
own personal beliefs about prostate cancer screening.  If physicians are pro prostate 
cancer screening, they can find recommendations to support that activity, and if they do 
not support screening, they can find the evidence for that as well.  Until the screening 
trials provide the definitive answers about prostate cancer screening, it will be left to 
physicians and men to make their own decisions about whether to have a PSA test or not 
for screening for prostate cancer. 
These studies highlight the opportunity that exists in Saskatchewan for further 
research on PSA testing and prostate cancer.  We have an excellent population-based 
cancer registry, PSA data that resides in only two locations for the province and is in 
electronic format, and linkage capabilities to other data sources at Saskatchewan Health.  
The PSA data used in these projects is likely unique in the world in that all PSA records 
are accessible and we have the ability to determine whether PSA testing was in men with 
or without known prostate cancer at the time of their test.    
Saskatchewan has a Health Information Protection Act which is fairly stringent 
for conducting such linkage studies.  Acquiring data from these sources and linking them 
is a very time consuming endeavor.  In future, it would be beneficial if this data was more 
readily available so that evaluations and research could be timelier. 
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9.0 STUDY LIMITATIONS 
The study was conducted to investigate the use of PSA testing and impacts on the 
Saskatchewan population.  Screening rates and associated measures such as sensitivity 
and specificity were estimated in the population.  Information about the reason for the 
PSA test was not available.  So while these measures were calculated, they certainly 
would be affected by more knowledge of risk in the men tested.  As it is, the screening 
rates are really more accurately prevalence rates.  The estimates of sensitivity and 
specificity would certainly be impacted by weeding out the higher risk men (with 
symptoms or family history of prostate cancer) which would be more common with 
increasing age.  Therefore, the estimates are really measures of the combined impact of 
all PSA testing for all men in the population, and not strictly speaking the screened group 
of low risk men.    
As well, the “true” disease status of all men in the population is not known.  It 
was possible to eliminate men who were already diagnosed with prostate cancer which 
was beneficial to estimate screening rates and the associated measures of sensitivity and 
specificity.  But it would be the case that some men in the group labeled “without cancer” 
would certainly have had prostate cancer.  Not every man in the population has a biopsy, 
even among men with elevated PSAs.  So there would be some contamination in the non 
cancer group with men who had not yet been diagnosed but will be in future.  At the same 
time, this is the reality of the real world situation, where not every man is thoroughly 
investigated for a host of reasons.  So the estimates of sensitivity and specificity are 
reflective of the real population circumstance.   
The study period covered five years at a point when PSA testing had been 
available in Saskatchewan already for seven years.  Some of the study results indicated 
men who had one PSA test during that period.  Given a seven year period prior to the 
study dates, it is very likely some percentage of these men were in fact not receiving their 
first PSA test, but rather subsequent ones.   
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There were also some missing PSA records from this five-year period.  In total the 
data contained about 80% of all PSA tests in the province.  Therefore all of the 
prevalence and screening rates were certainly underestimated, potentially by as much as 
20% and more likely in the Saskatoon Health Region.  As well, the data covered a time 
when PSA testing was in fact still on the increase.  In the first year of this study, 1997, 
there were about 50,000 PSA tests reportedly done in Saskatchewan.  By the end of the 
study period, 2001, there were about 80,000 reported.  So the prevalence and screening 
rates reflect this period when the testing volumes were still be increasing.  After 2001, it 
is known that the PSA testing levels became stable in the 80,000 to 90,000 range of tests 
per year.  So for the five-year period of this current study, a total of about 315,000 PSA 
tests were done, of which 250,000 were retrieved, but the subsequent five years 2002-
2006 would have had well over 400,000 tests, a minimum 27% increase from the 
previous five-year period.   
The Saskatchewan Cancer Registry apparently is missing some records for 
prostate cancer cases diagnosed in men 80 and over.  As witnessed, the incidence rate for 
men in their 70s has over taken the rate for men 80 and over, contrary to what would be 
expected for a disease that is so age related.  Younger men would be more aggressively 
investigated and as such much more likely to have a biopsy to confirm disease than older 
men who would have less life expectancy and more co-morbid conditions.  This made 
interpretations of the 80 and over group difficult and as such this group had to be omitted 
from some analyses. 
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10.0 STUDY IMPLICATIONS 
Limitations aside, the study reveals some striking results that do support the 
requirement for action and policy or guideline development.  In Saskatchewan, we must 
realize and accept that prostate cancer screening is in fact very common.  The question is 
not whether we should be screening or not, but rather given that we are screening, how do 
we best control and manage the activity so over testing can be limited?  The only solution 
to preventing use of the PSA test would be for the government to de-insure it, which in 
all probability is highly unlikely after 18 years of availability, even if the current 
screening trials reveal little or no benefit.  The implication in Saskatchewan is, given we 
are likely already screening over 80% of men aged 50 to 79, we must better manage use 
of the PSA test and ensure appropriate follow-up for men with high PSA levels. 
Even though information was missing about the reason for the PSA test, the 
variation in testing patterns by age group, the frequency of testing in men, and the 
geographic variations indicate physicians are unsure how or when to use this test and 
what appropriate follow-up should occur.  There are many different screening guidelines 
in existence however, and currently no randomized trial evidence of overall mortality 
benefit.  So we will need to develop an action plan to manage the use of the PSA test that 
will appropriately fit in the Saskatchewan context.   
An action plan will need to include a number of elements.  First, information and 
recommendations about appropriate use of the PSA test based on the most current 
evidence needs to be developed.  This will help ensure that men who do not need a PSA 
test, for example men under 50 years of age with no symptoms of disease or men over 80, 
are not screened.  As well, recommendations about repeat testing in asymptomatic men 
would hopefully prevent some men from being tested more often than necessary.  
Development of recommendations will require thorough investigation of current 
knowledge and understanding of existing guidelines as they relate to the experience in 
Saskatchewan.   
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Secondly, getting this information to the providers will require a significant 
education component.  A communications strategy for these recommendations would 
need to be developed, to ensure the information gets to providers in the most concise and 
practical method to improve and maximize uptake.  How the information is packaged and 
provided would be key elements.   
Establishing such an action plan for using the PSA test will require a 
multidisciplinary approach.  A steering committee including partners representing general 
practitioners, urologists, Cancer Agency experts, and the labs involved in PSA analysis 
would need to be involved so that physicians will be more likely to support the 
recommendations.  Non provider groups might need to be involved as well, such as the 
Prostate Cancer Support Network, the Cancer Society and the Ministry of Health. 
Saskatchewan is in a unique position as well to monitor use of the PSA test at the 
population level and track practice patterns and outcomes.  There is an opportunity to 
make great contributions to the analysis and impact of population-based PSA screening 
for prostate cancer, given we are essentially already doing population level screening.  
The Saskatchewan Cancer Agency has a Prevention Program for Cervical Cancer (PPCC) 
screening program using PAP testing that could be a model for prostate cancer.  In the 
PPCC, only two labs analyze PAP tests and both labs submit the test results electronically 
to a central database managed by the Saskatchewan Cancer Agency.  A similar approach 
could be done with PSA tests, housing the data in a central database.  This would enable 
the Agency to track PSA use, follow-up patterns for men tested, evaluate outcomes and 
become an important information source for physicians about use of the test.   
The ongoing screening trials should be publishing results in 2009.  Once these 
have been reported, a decision could be made about the development of an official 
program for prostate cancer screening.  If the population-based database is already in 
place, it will be easy to incorporate a program with decision rules based on the trial 
results.  
A number of recommendations are suggested.  
1) Results of these projects need to be shared with major stakeholders; 
Saskatchewan Health, the two labs that analyze PSA in Saskatchewan, the 
Saskatchewan Cancer Agency, and the urologists and general practitioners in the 
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province.  Recommendations should be developed about the use of the PSA test in 
Saskatchewan.  While it is not presently reasonable to assume testing can be 
prevented since it is so entrenched in our population, we should at least be able to 
provide recommendations and information to better control who is tested and how 
often, to eliminate waste and unnecessary use of health system resources. 
2) The Saskatchewan Cancer Agency should investigate the possibility of 
developing a provincial PSA database, with data electronically provided by the 
labs that analyze PSA samples.  An up-to-date population-based database would 
provide an excellent opportunity for monitoring and evaluation, and would be 
required in the future should organized screening for prostate cancer be 
recommended when the ongoing screening trials are completed.  The 
Saskatchewan Cancer Agency has experience in this regard, as it houses all the 
PAP smear data for the province in a similar fashion, where the labs electronically 
send PAP test results to a central database maintained by the Agency.  Such a 
PSA database would be unique and provide much more timely analysis and 
evaluation of PSA use.   
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11.0 CONCLUSION 
Saskatchewan provides an excellent test population to examine the impact of PSA 
testing on prostate cancer and outcomes due to the unique availability of both the data 
and the test, which is available free of charge to all men in the population.   
PSA testing is extensively practiced in Saskatchewan with over 60% of men 50 to 
79 years of age having at least one PSA test between 1997 and 2001.  Many tests were 
done in men under 50 and even under 40 years of age, and many were done in men over 
80.  Lots of men also had more than one test in the five-year period and this occurred in 
all age groups, including men less than 40.  A majority of PSA tests were ordered by 
general practitioners but there were also geographic variations in testing prevalence.  
There is considerable testing in age ranges that simply is not be supported by any 
evidence whatsoever.  Access to GPs and universality of health benefits are drivers of 
PSA use.   
Knowledge of free-PSA level as a percentage of total PSA was found to improve 
cancer detection while slightly lowering the overall biopsy rate in men 50 to 79 years.  
We experienced a natural experiment by using the reflex testing process at the Pasqua 
Hospital lab that applied to the whole population.  Reflex testing and knowledge of the 
fPSA showed better discrimination for biopsy and cancer detection.  
Prostate cancer incidence follows the pattern of PSA testing in the population. 
More testing results in more new cases diagnosed. PSA testing has shifted the diagnosis 
of prostate cancer to more cases that are organ confined moderately differentiated.  
Clinical management has changed over time, with most prostate cancer now diagnosed by 
biopsy and treated with surgery.  Although PSA has been around for 18 years, and more 
favourable cases are diagnosed, no change in mortality has yet been realized.   
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13.0 APPENDIX 1 
Prostate Specific Antigen (PSA) is found in the blood in three molecular forms: free PSA, 
PSA complexed with • -1 antichymotrypsin, and PSA complexed with • -2 
macroglobulin.  Commonly used immunoassays measure total PSA, the sum of the free 
and complexed forms, but a specialized assay is now available to measure the free form, 
which is expressed as a ratio of the total PSA.  
Recent studies have shown that the measurement of the ratio of free-to-total PSA can 
improve specificity for distinguishing between benign prostatic hyperplasia (BPH) and 
prostatic carcinoma.  Patients with higher ratios of free PSA are more likely to have 
benign findings and patient with lower ratios are more likely to have prostatic carcinoma.  
The following guidelines are utilized for the interpretation of free PSA values in 
establishing patient-specific risk for prostatic carcinoma:  
• Free-to-total PSA ratios of greater than 0.24 are more likely to be benign prostatic 
hyperplasia. As the ratio increases so does the likelihood of BPH.  
• Free-to-total PSA ratios of less than 0.10 are more likely to be prostatic carcinoma. 
As the ratio decreases, the likelihood of carcinoma increases. 
• Free-to-total PSA ratios between 0.10 and 0.24 show substantial overlap of clinical 
findings with both malignant and benign diagnoses.  
• There is some overlap of clinical findings throughout the range of free-to-total PSA 
ratios. Measurement of free PSA and the resulting ratio is not an absolute test for 
malignancy.  
133 
• The free-to-total PSA ratio is most useful in patients with total PSA values between 4 
to 10 • g/L.  
All total PSA with a value from 4 to 10 • g/L inclusive will have a free PSA 
automatically reflexed and the free-to-total PSA ratio reported. Free PSA cannot be 
ordered as an individual test. 
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